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Abstract
Clinical effectiveness of interventions for treatment-resistant
anxiety in older people: a systematic review
Samantha Barton,1* Charlotta Karner,1 Fatima Salih,1
David S Baldwin2 and Steven J Edwards1
1BMJ Technology Assessment Group, London, UK
2Faculty of Medicine, University of Southampton, Southampton, UK
*Corresponding author
Background: Anxiety and related disorders include generalised anxiety disorder, obsessive–compulsive
disorder, panic disorder, post-traumatic stress disorder and phobic disorders (intense fear of an object or
situation). These disorders share the psychological and physical symptoms of anxiety, but each disorder has
its own set of characteristic symptoms. Anxiety disorders can be difficult to recognise, particularly in older
people (those aged over 65 years). Older people tend to be more reluctant to discuss mental health
issues and there is the perception that older people are generally more worried than younger adults.
It is estimated that between 3 and 14 out of every 100 older people have an anxiety disorder. Despite
treatment, some people will continue to have symptoms of anxiety. People are generally considered to be
‘resistant’ or ‘refractory’ to treatment if they have an inadequate response or do not respond to their first
treatment. Older adults with an anxiety disorder find it difficult to manage their day-to-day lives and are at
an increased risk of comorbid depression, falls, physical and functional disability, and loneliness.
Objective: To evaluate the effectiveness of pharmacological, psychological and alternative therapies in
older adults with an anxiety disorder who have not responded, or have responded inadequately,
to treatment.
Data sources: Electronic databases (MEDLINE, MEDLINE In-Process and Other Non-Indexed citations,
EMBASE, The Cochrane Library databases, PsycINFO and Web of Science) were searched from inception to
September 2013. Bibliographies of relevant systematic reviews were hand-searched to identify additional
potentially relevant studies. ClinicalTrials.gov was searched for ongoing and planned studies.
Review methods: A systematic review of the clinical effectiveness of treatments for treatment-resistant
anxiety in older adults was carried out.
Results: No randomised controlled trial or prospective comparative observational study was identified
meeting the prespecified inclusion criteria. Therefore, it was not possible to draw any conclusions on
clinical effectiveness.
Limitations: As no study was identified in older adults, there is uncertainty as to which treatments are
clinically effective for older adults with an anxiety disorder who have not responded to prior treatment.
The comprehensive methods implemented to carry out this review are a key strength of the research
presented. However, this review highlights the extreme lack of research in this area, identifying no
comparative studies, which is a marked limitation.
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Conclusions: Specific studies evaluating interventions in older adults with an anxiety disorder who have
not responded to first-line treatment are needed to address the lack of evidence. The lack of evidence in
this area means that older adults are perhaps receiving inappropriate treatment or are not receiving a
particular treatment because there is limited evidence to support its use. At this time there is scope to
develop guidance on service provision and, as a consequence, to advance the standard of care received by
older adults with a treatment-resistant anxiety disorder in primary and secondary care. Evaluation of the
relative clinical effectiveness and acceptability of pharmacological and psychological treatment in older
adults with an anxiety disorder that has not responded to first-line treatment is key future research to
inform decision-making of clinicians and patients. An important consideration would be the enrolment of
older adults who would be representative of older adults in general, i.e. those with multiple comorbid
physical and mental disorders who might require polypharmacy.
Study registration: The protocol for the systematic review is registered on PROSPERO (registration
number CRD42013005612).
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Anxiety and related disorders include generalised anxiety disorder, obsessive–compulsive disorder, panicdisorder, post-traumatic stress disorder and phobic disorders (an intense fear of an object or situation).
These disorders share psychological and physical symptoms of anxiety, but each disorder has its own set of
characteristic symptoms. Most people with an anxiety disorder are diagnosed by the age of 40 years, but a
few people will develop an anxiety disorder at older age (after the age of 65 years). Anxiety disorders can
be difficult to recognise in older people, as there is the perception that older people are generally more
worried than younger adults. In addition, older people are often reluctant to acknowledge that they are
experiencing a mental health problem. It is estimated that the number of older people with an anxiety
disorder is between 3 and 14 out of every 100 older people.
Treatments for anxiety include psychological therapies, pharmacological treatments and complementary
therapies. Choosing a treatment for an older person with anxiety can be complicated. Older people typically
have several medical conditions that need treatment and, because of the number of medications they are
potentially taking, are at an increased risk of having side effects to potential treatments for anxiety. Some
people will continue to feel anxious after initial treatment, which is known as treatment-resistant anxiety.
In younger people, adding a second psychotropic drug to a first drug has been found to lower anxiety in
some disorders. However, it is not known whether this treatment strategy is effective in older people.
At this time, there is little research on treatment-resistant anxiety in older people, and there is no
resource that summarises the evidence for how effective the various therapies available are at treating
treatment-resistant anxiety disorders in older people or how they compare against each other. This
systematic review aimed to assess how well the treatments for treatment-resistant anxiety work in older
people and how they compare with each other in improving the symptoms of anxiety. Other goals were
to assess the adverse effects associated with the various treatments and to identify gaps in the evidence
available. The project team searched the literature for evidence around the effectiveness of treatments and
any side effects associated with them. No study assessing treatments for treatment-resistant anxiety in
older adults was identified, underscoring the lack of research in this clinical area.
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Scientific summary
Background
Anxiety disorders can affect people of all ages. In contrast to the appearance of anxiety that might be
experienced during a stressful event, for example when taking a driving test, an anxiety disorder persists for a
longer period of time and symptoms can progressively worsen if not treated. The onset of anxiety disorders is
typically between childhood and young adulthood, with relatively few people (< 1%) developing an anxiety
disorder for the first time after the age of 65 years. Recognition of the difficulties in differentiating symptoms
of anxiety from physiological and physical changes (e.g. changes in sleep pattern) arising from the ageing
process, together with the reluctance of many people to acknowledge psychological difficulties, has led to
the realisation that anxiety in older people tends to be under-detected and under-treated. Many people with
an anxiety disorder also suffer from various comorbidities, both physical and psychological, that can further
complicate diagnosis and worsen the outcome of the disorder. Therefore, a comprehensive evaluation by an
experienced clinician is needed. Disorders affecting physical health are common in older adults, and older
adults often attribute symptoms of anxiety to their physical illness, which could result in non-diagnosis of
their anxiety disorder.
The specific cause of symptoms in each anxiety disorder is not well established and the underlying
aetiology of the disorders is yet to be fully elucidated. Treatments offered for an anxiety disorder are
determined by the presumed underlying cause, though initial treatment might involve education and active
monitoring. People whose symptoms of anxiety do not improve might subsequently be recommended to
undergo psychological therapy or be prescribed a pharmacological treatment. Despite initial treatment,
many people will continue to have symptoms of anxiety. Although there is no accepted definition of
treatment resistance in anxiety disorders, people are generally considered to be resistant to treatment if
they have made an inadequate response (either no response or only a partial response) or do not respond
(refractory) to first-line treatment, irrespective of whether the first-line treatment was a psychological or
pharmacological intervention.
As with younger adults, the course of anxiety disorders in older people is typically chronic or episodic in
nature, and most disorders are unlikely to remit completely, even with long-term treatment. Compared
with people of the same age and with what would be categorised as normal worries, older people with
an anxiety disorder frequently experience greater difficulty in managing their day-to-day lives and are at
an increased risk of comorbid depressive disorders, falls, physical and functional disability, and loneliness.
Furthermore, the presence of an anxiety disorder is associated with reduced adherence with medical
treatment, and long-term medical conditions are potentially exacerbated, which can result in a further
loss of independence and increased reliance on family or carers. Anxiety has a considerable detrimental
effect on quality of life (QoL) for both the older person with an anxiety disorder and that of any carers.
Objectives
The aim of the review was to evaluate the clinical effectiveness of medical, psychological and alternative
therapies for treatment-resistant anxiety in older people.
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Methods
A systematic review of the clinical effectiveness of treatments for treatment-resistant anxiety in older adults
was carried out. Electronic databases (MEDLINE, MEDLINE In-Process and Other Non-Indexed citations,
EMBASE, The Cochrane Library databases, PsycINFO and Web of Science) were searched from inception to
September 2013. Bibliographies of relevant systematic reviews were hand-searched to identify additional
potentially relevant studies. ClinicalTrials.gov was searched for ongoing and planned studies.
Studies eligible for inclusion in the review were randomised controlled trials (RCTs) and prospective
comparative observational studies (matched control studies, case series and case–control studies) evaluating
pharmacological, psychological and alternative therapies for treatment-resistant anxiety in older people.
Study selection was carried out independently by two reviewers. Studies were eligible for inclusion in the
review if they evaluated at least one intervention of interest, included only people aged ≥ 65 years or
reported data for a subgroup of patients aged ≥ 65 years, compared the intervention with another
intervention of interest and reported at least one of the following outcomes: reduction in symptoms of
anxiety; response defined as proportion of people experiencing ≥ 50% reduction in symptom score from
baseline); remission; functional disability; sleep quality; development of, or change in, symptoms of
depression; adherence to treatment; QoL; carer outcomes; and adverse effects.
Summary of findings of included studies
No RCT or prospective comparative observational study was identified meeting the prespecified inclusion
criteria. Therefore, it was not possible to draw conclusions on clinical effectiveness of interventions for
treatment-resistant anxiety in older people.
Discussion
As no study was identified evaluating treatments in older adults, there is uncertainty as to which
treatments are clinically effective for older adults with an anxiety disorder that has not responded to prior
treatment. Older adults present with manifestations of anxiety different from those of younger adults.
Taken together with the observation that response to treatment is often poorer in later life, it is probably
inappropriate to extrapolate results of clinical effectiveness of interventions in anxiety disorders in younger
adults to older adults.
Strengths and limitations
To our knowledge, the review reported here is the first systematic review of interventions for
treatment-resistant anxiety in older adults. The comprehensive methods implemented to carry out the
review are a key strength of the research presented. However, the review highlights the lack of research in
this area, identifying no comparative studies, which is a limitation. Although multiple RCTs were identified
that evaluated clinical effectiveness of interventions for treatment-resistant anxiety disorders, many limited
inclusion to adults aged ≤ 65 years. Of those studies that included people ≥ 65 years, the mean ages
reported at baseline suggest that most included people were much younger than 65 years. The potentially
small number of people likely to be aged 65 years and over in the studies identified restricts the practicality
and feasibility of carrying out a meta-analysis based on individual patient data. In addition, as the studies
identified evaluated a range of treatments across various anxiety disorders, it is likely that the number of
events for each treatment would be low, which would probably lead to considerable uncertainty in
the results.
SCIENTIFIC SUMMARY
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Conclusions
Studies evaluating interventions in older adults with an anxiety disorder that has not responded to first-line
treatment are needed to address the lack of evidence in this area. This lack of evidence means that older
adults are perhaps receiving inappropriate treatment, or are not receiving a particular treatment because
there is no evidence to support its use. There is scope to develop guidance on service provision and,
as a consequence, to advance the standard of care received by older adults with a treatment-resistant
anxiety disorder in the primary and secondary settings.
Study registration
The protocol for the systematic review is registered on PROSPERO (registration number CRD42013005612).
Funding
The National Institute for Health Research Health Technology Assessment programme.
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Chapter 1 Background
Description of health problem
Anxiety disorders can affect people of all ages. In contrast to the appearance of anxiety that might be
experienced during a stressful event, for example when taking a driving test, an anxiety disorder persists
for a longer period and symptoms can progressively worsen if not treated. Anxiety disorders can develop
at any age, but onset typically occurs between childhood and young adulthood, with few people
(< 1%) developing an anxiety disorder for the first time after the age of 65 years.1 A US-based study
(9282 English-speaking respondents aged ≥ 18 years) reported the median age at onset of anxiety
disorders to be 11 years.2 Although anxiety disorders among older people (≥ 65 years) are less common
than in younger adults, it is acknowledged that the frequency in older adults is considerably higher than
previously thought. Recognition of the difficulties in differentiating symptoms of anxiety from physiological
and physical changes (e.g. changes in sleep pattern) arising from the ageing process, together with a
common reluctance of older people to acknowledge psychological difficulties, has led to the realisation
that anxiety in older people has been under-detected and under-treated.1,3
Many people with an anxiety disorder also have other medical conditions, both physical and psychological,
that can further complicate diagnosis and worsen the long-term outcomes of the anxiety disorder.
Of other anxiety and psychological disorders, depression is the most common comorbidity among younger
and older adults.1 Studies suggest that between 13%4 and 23%5 of people aged 55 years and older with
a diagnosis of an anxiety disorder will also meet the criteria for a diagnosis of a major depressive disorder.
One study in adults aged > 70 years found that 29.4% of those with an anxiety disorder had a comorbid
depressive disorder.6 In comparison, 20% of younger adults (aged 18–54 years) with a diagnosis of any
anxiety disorder in the previous 6 months are likely to receive a simultaneous diagnosis of some type of
mood disorder. Disorders affecting physical health are common in older adults, and older adults are more
likely to attribute their symptoms of anxiety to their physical illness, which could result in non-diagnosis of
their anxiety disorder.1 Development of an anxiety disorder has been linked with thyroid problems
(e.g. hypothyroidism or hyperthyroidism), respiratory and gastrointestinal conditions, arthritis, migraine
headaches and allergic conditions.7
Treatments offered for an anxiety disorder are determined by the underlying cause of anxiety, though
initial treatment might involve education and active monitoring. People whose symptoms of anxiety do not
improve might subsequently be recommended to undergo psychological therapy or be prescribed a
pharmacological treatment. Despite treatment, some people will continue to have symptoms of anxiety.
With the exception of obsessive–compulsive disorder (OCD), there is no common definition as to what
constitutes treatment resistance or treatment refractoriness in anxiety disorders.8 People are generally
considered to be resistant or refractory if they have an inadequate response (resistant) or do not respond
(refractory) to first-line treatment, irrespective of whether the first-line treatment was a psychological or
pharmacological intervention.
Diagnosis of an anxiety disorder
The term ‘anxiety disorder’ encompasses a broad range of conditions that manifest with symptoms of
anxiety. Two major classification systems that can be used as a basis for differentiation between the
different types of anxiety disorders are the Diagnostic and Statistical Manual of Mental Disorders (DSM)9,10
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and the World Health Organization’s International Classification of Diseases (ICD).11 Until 2013, the DSM
identified 12 distinct anxiety disorders that could be captured within seven headings:9
l generalised anxiety disorder (GAD)
l OCD
l phobias, encompassing specific (simple) phobias and social phobia (also known as social
anxiety disorder)
l stress disorders, including post-traumatic stress disorder (PTSD) and acute stress disorders
l panic disorder (with or without agoraphobia)
l anxiety disorders owing to known physical causes (e.g. medical conditions and symptoms caused by
drug misuse)
l anxiety disorder not otherwise specified (covers symptoms not meeting the criteria for other
anxiety disorders).
In 2013, the latest version of the DSM (version 5) was released.10 Within the updated DSM, OCD is
separated from the other anxiety disorders and is presented in a discrete chapter alongside related
disorders. In addition, the stress disorders (PTSD and acute stress disorder) now lie within the chapter
covering trauma- and stressor-related disorders. Separation anxiety disorder and selective mutism, which
had previously been classified as ‘Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence’,
were added to the anxiety disorders.12 An accompanying comment on the revisions highlights that the
changes underscore the discrete nature of the individual anxiety disorders, but that the sequential
presentation of the chapters in the manual reflects the interconnectedness of the conditions.
The ICD-10 lists anxiety disorders under the general heading ‘Neurotic, stress-related and somatoform
disorders’, which comprises the subgroups of:11
l phobic anxiety disorders (e.g. agoraphobia with or without panic disorder, social phobia and
specific phobias)
l other anxiety disorders (e.g. panic disorder, GAD, and mixed anxiety and depressive disorder)
l OCD
l reaction to severe stress and adjustment disorders (acute stress reaction, PTSD and
adjustment disorders)
l dissociative (conversion) disorders (e.g. dissociative amnesia and dissociative stupor)
l somatoform disorders (e.g. somatisation disorder and hypochondriacal disorders)
l other neurotic disorders (e.g. neurasthenia).
Diagnosis of an anxiety disorder can be challenging, particularly in older people. Symptoms of anxiety can
be similar to those of other psychological conditions, such as depression, and the frequent presence of
comorbid mental disorders further complicates diagnosis across all age groups.13 Differentiating excessive
anxiety from concerns around a recent distressing experience in older people, for example after a fall, can
also prove difficult.14 Anxiety in such scenarios might be expected by both the patient and the clinician and,
therefore, the diagnosis of an anxiety disorder might not be considered. Additionally, some older people
might have beliefs about emotional problems that make them reluctant to raise concerns about anxiety and
it has also been recognised that older adults from ethnic minority groups often have different manifestations
of anxiety. Both of these factors increase the difficulty in recognising anxiety in this age group.13,15
Compared with younger adults, older people often present to their clinician with non-specific symptoms,
such as tiredness, or symptoms that are frequently related to the ageing process, such as a changing sleep
pattern.16 A common symptom of anxiety is deterioration in memory, which could be interpreted as signs
of cognitive decline or onset of dementia.17 Across all age groups anxiety disorders are often associated
with pain and physical symptoms that could be a sign of heart disease or another physical illness7 and,
in these cases, identifying a presumed physiological cause is likely to be the focus of initial clinical
investigations. Moreover, older people frequently require multiple concomitant treatments to manage
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comorbid psychological and chronic medical conditions, and symptoms of anxiety could be thought to be
associated with pharmacological treatment.
If an anxiety disorder is suspected, standardised screening questionnaires can initially be used to evaluate
the presence and severity of anxiety. Validated screening tests include the Beck Anxiety Inventory,
Spielberger State–Trait Anxiety Inventory, the Generalised Anxiety Disorder 7 (GAD-7) assessment and the
Hospital Anxiety and Depression Scale.18 The individual scales evaluate a set number of items to determine
the severity of a patient’s anxiety, with the number of items varying across the rating scales. The rating
scales differ in that they were designed to assess anxiety in different patient groups; for example, the Beck
Anxiety Inventory focuses on somatic symptoms of anxiety and was developed to differentiate between
anxiety and depression. By contrast, the Hospital Anxiety and Depression Scale evaluates the presence of
symptoms of anxiety and depression in physically ill people.18 The effects of variation in language,
education and culture across ethnic groups can lead to variation in judging the severity of patients’
symptoms.15 Although useful for initial evaluation and assessing treatment response, the generalised
questionnaires are inadequate for determining which specific anxiety disorder is present. A formal clinical
diagnostic assessment by an experienced clinician is required to categorise the disorder (based on criteria in
the DSM-V or ICD-10).
Psychological and physical symptoms of anxiety are common across all anxiety disorders.19 Some of the
common psychological manifestations of anxiety include difficulty concentrating, feelings of trepidation,
stress and restlessness, whereas common physical symptoms include fatigue, heart palpitations and
trembling. In addition to the general symptoms, each anxiety disorder is associated with characteristic
symptoms. Symptoms or triggers that can distinguish one disorder from another are listed in Table 1.20
DSM-IV and ICD-10 criteria for the individual anxiety disorders are presented in Appendix 1.
Aetiology, pathology and prognosis
The specific cause of symptoms in each anxiety disorder is not well established and the underlying
pathology of the disorders has yet to be fully elucidated. It is thought that a complex combination of
genetic, environmental, psychological and developmental factors contribute to the development of an
anxiety disorder.21 Various factors have been found to increase the risk of developing an anxiety disorder,
with some identified as specifically increasing this risk in older adults (summarised in Box 1).1,19 Evidence
indicates that susceptibility to anxiety disorders can be determined early in life. Early-life trauma has long
been thought to increase the subsequent risk of developing a mental health illness.21
When a threat is perceived, various neurotransmitters and other chemical messengers, including circulating
hormones, are released to modulate the neural circuitry involved in the generation of feelings of fear and
anxiety.22 The chief hormone involved in the autonomic nervous system is the catecholamine ‘adrenaline’
(also known as epinephrine), produced by the adrenal glands. Adrenaline triggers a physical response to
stress, including increased heart rate and breathing rate.22 At the same time another hormonal system,
TABLE 1 Symptoms and triggers associated with individual anxiety disorders20
Anxiety disorder Disorder-specific symptoms
GAD Constant worries and fears
OCD Unwanted persistent or repetitive thoughts or behaviours that seem impossible to stop or control
Social phobia A debilitating fear of being seen negatively by others and humiliated in public
Specific phobia Excessive or irrational fear of a specific object or situation
PTSD Extreme anxiety disorder that can occur in the aftermath of a traumatic or life-threatening event
Panic disorder Repeated, unexpected panic attacks as well as fear of experiencing another episode
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the hypothalamo–pituitary–adrenal axis, initiates a pathway involving several hormones and other
messengers. The culmination of the various signalling interactions is the release of adrenal hormones,
called glucocorticoids, of which cortisol is the most important.22,23 Cortisol causes a rapid release of
the body’s energy stores to maintain blood sugar levels and also suppresses any immune response.
Dysregulation of the hypothalamo–pituitary–adrenal axis is known to be associated with an increased risk
of development of major depression.24 Furthermore, the ageing brain is less able to downregulate the
hypothalamo–pituitary–adrenal axis and is more susceptible to physiological stressors.25 Thus, in older
adults chronic anxiety can cause hyperactivity of this system, which can detrimentally affect memory and
executive function.
The main neurotransmitters implicated in anxiety disorders are noradrenaline, serotonin, dopamine and
gamma-aminobutyric acid (GABA).26 The discovery that anxiolytic (anti-anxiety) drugs interact with
neurotransmitters led to the proposal that abnormal activity in the brain is a physiological characteristic
of anxiety.21
Imaging of brain activity during exposure to triggers of anxiety has suggested that the amygdala and the
hippocampus have an integral role in eliciting feelings of fear and anxiety.21,26 The amygdala is located deep
in the anterior medial section of each temporal lobe and is thought to be involved in memory storage and
communication.27 It is thought that the amygdala facilitates signal transfer between the components of the
brain that process incoming sensory signals and those that interpret the signals. An imbalance of the
signalling pathway, possibly resulting from overactivity of the amygdala, is thought to contribute to
excessive anxiety.27 The amygdala functions as a warning system, alerting for potential impending threat
and activating the nervous system to generate feelings of fear or anxiety. The central part of the amygdala is
thought to store emotional memories and, thus, could have a role in the development of a specific phobia.
BOX 1 Risk factors for developing an anxiety disorder
Risk factors for general population19
l Being female.
l Traumatic experience in either childhood or adulthood.
l Physical illness (e.g. thyroid problems and chronic medical conditions).
l Stress over a prolonged period of time (e.g. ongoing concern about finances).
l Genetic predisposition.
l Drug or alcohol abuse.
Risk factors for older adults1
l Being female.
l Having multiple chronic medical conditions (particularly chronic obstructive pulmonary disease,
cardiovascular disease, thyroid disease and diabetes).
l Being single, divorced or separated.
l Lower level of education.
l Perceived (self-reported) poor health.
l Sleep disturbance.
l Effects of medications (e.g. corticosteroids, antidepressants, stimulants and bronchodilators).
l Alcohol or prescription medication misuse or abuse.
l Physical limitations in daily activities.
l Stressful life events.
l Adverse events in childhood.
l Neuroticism or preoccupation with somatic (physical) symptoms.
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Located in the forebrain and forming part of the limbic system, which is the area of the brain that
responds to stress, the hippocampus is important in spatial navigation and the formation of memories.21
The hippocampus is involved in consolidating a life-threatening or traumatic event into a memory.
Some studies suggested that the hippocampus is smaller in some people who have PTSD, with the change
in size28–31 thought to be induced by sustained exposure to cortisol, which is known to damage the
hippocampus23 during a prolonged period of stress.32 However, recent research involving identical
(monozygotic) twins suggests that reduced hippocampal volume is predetermined and volume is linked
with susceptibility to PTSD.33 Other studies in identical or non-identical (dizygotic) twins have found that all
the anxiety disorders have a moderately strong genetic basis, accounting for 30–40% of the probability of
a person developing an anxiety disorder.34,35
The extent to which environmental factors determine the risk of developing an anxiety disorder is not
established. However, one environmental factor known to be linked with the risk of a person developing
an anxiety disorder is the childhood relationship with parents.36,37 Positive parenting experiences are
important to provide children with a feeling of security. Family conflict, lack of structure and discipline, and
overprotection, amongst others, have been identified as parental experiences that predispose a person to
developing an anxiety disorder, either during childhood or in later life.37
Categorisation of treatment resistance in anxiety disorders is complex. It has been recommended that the
assessment of remission and recovery in anxiety disorders includes an assessment of functional status.38
Recognition of treatment resistance is further complicated by the frequent presence of symptoms of more
than one anxiety disorder and the presence of a comorbid disorder that potentially disrupts treatment.
Response to treatment or, conversely, non-response to treatment in anxiety disorders has been investigated
in various studies.38 Factors thought to contribute to poor response to treatment have been divided into
four categories (outlined in Box 2): pathology, environment, patient and clinician. Difficulty in diagnosing
treatment resistance is affected by the same problems encountered when diagnosing an anxiety disorder,
including changes in, and variation across, criteria used to categorise anxiety disorders, under-recognition
of the disorder and use of clinically inadequate doses of pharmacological agents in initial treatment.
As with younger adults, the course of established anxiety disorders in older people is typically chronic
or episodic in nature, and most disorders are unlikely to remit completely, even with long-term
treatment.39 One US-based study evaluating people with GAD (164 people) reported a mean age at onset
of an anxiety disorder of 21 years and an average duration of illness of about 20 years.40 Studies suggest
that anxiety disorders are more chronic than other common mental disorders and that comorbid
depression and anxiety has a worse prognosis.41 The presence of an anxiety disorder has been identified as
an independent risk factor for subsequent onset of suicidal ideation and attempts.42 In all age groups,
the frequent comorbidity of anxiety disorders, depression, and alcohol and drug misuse complicates the
evaluation of long-term prognosis. In clinical trials involving a mixed-age population and different anxiety
disorders, remission rates of 20–47% have been reported.43 The study evaluating people with GAD found
that, despite treatment, only 25% of patients achieved symptomatic remission from GAD at 3 years,40
with a risk of relapse over the subsequent year of about 15%; risk of relapse for those achieving partial
symptomatic remission increased to 30%.40
Incidence and prevalence
Data reported on prevalence and incidence vary across studies. This disparity can be attributed to different
methodological procedures used, including sampling, with some studies using nationally representative
samples and others using convenience samples; differences in the tools used to diagnose an anxiety
disorder; and differences in the anxiety disorders included in the evaluation.1
The prevalence of anxiety disorders in older people exceeds that of late-life depression and cognitive
dysfunction,44 with estimated rates of anxiety disorders ranging from 3.2% to 14.2% in people aged over
65 years.1 In England during 2007, 2.28 million people were estimated to have an anxiety disorder, with
13% of those being aged over 65 years.45 The prevalence of anxiety disorders is even higher among older
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people who are housebound and require home care, those who live in residential care facilities (e.g. a
nursing home or assisted living) and those who have a chronic medical illness. In addition, 15–20% of
older people experience symptoms of anxiety that, although debilitating, do not meet criteria for a
psychiatric diagnosis.3 Most people with a primary anxiety disorder experienced the onset of the condition
before the age of 41 years (90%), with 75% of people diagnosed with an anxiety disorder before the
age of 21 years.46
A UK-based epidemiological survey of common mental disorders [including depression, GAD, panic
disorder, phobias (in general) and OCD] reported GAD to be the most common anxiety disorder affecting
people in the UK, with a prevalence of 4.4%. The prevalence of PTSD was 3.0%, and only a small
proportion of people (< 1.5%) met diagnostic criteria for the remaining disorders.47 A review of the
literature on prevalence of anxiety disorders in older people identified considerable variation in prevalence
of the individual disorders (summarised in Table 2).1 The results reported in the review suggest that
estimates of prevalence are highest for social phobia (with or without agoraphobia) and GAD. However,
elsewhere, it has been reported that GAD is the most common anxiety disorder affecting older adults,
with a prevalence of 3.1–11.2%.3 The authors of this comprehensive review note that, because of
methodological issues identified earlier, it is not possible to draw definitive conclusions on prevalence.3
Data on prevalence of treatment-resistant anxiety in older people were not identified.
BOX 2 Factors thought to be involved in poor response to treatment in anxiety disorders
Pathology related
l Exact underlying pathophysiology is unknown.
l Multiple neurotransmitters participation and interaction.
l Complex receptor and feedback structure of every single transmitter system.
l Diagnosis – dimension approach.
l Genetics of the disorders overlap and unclear what is inherited.
l Current biological treatments are empirical and have limitations.
l Cognitive–behavioural theory is disconnected from biological substrate.
Environment related
l Severe stressors.
l Childhood stressors.
l Long-term persistent stressors.
l Life cycles.
Patient related
l Severity.
l Medical comorbidity.
l Psychiatric comorbidity.
l Non-compliance.
l Cultural factors.
Clinician related
l Lack of knowledge in primary care.
l Cognitive–behavioural theory is disconnected from biological substrate.
l Cost leading to limited doctor–patient relationship.
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Impact of health problem
When comparing older people with an anxiety disorder with people of the same age with what would be
categorised as ‘normal’ worries, older people with an anxiety disorder frequently experience greater
difficulty in managing their day-to-day lives and are at an increased risk of comorbid depressive disorders,
falls, physical and functional disability, and loneliness.1,3 Furthermore, the presence of an anxiety disorder
is associated with reduced compliance with medical treatment and potential exacerbation of chronic
conditions, which can result in loss of independence and increased reliance on family or carers. Anxiety has
a considerable detrimental effect on the quality of life (QoL) of both the older person with an anxiety
disorder and their carers.
Significance for the NHS
As a result of changing demographics, it is estimated that the number of people with an anxiety disorder
in England will grow to 2.56 million by 2026, with the largest increases observed in older age groups.45
Compared with data from 2007, it has been predicted that the number of people aged 85 years and older
with an anxiety disorder in England will increase by 66% by 2026.45 Anxiety disorders in older adults will
become a source of increasing personal and societal cost.
Current service provision
The National Institute for Health and Care Excellence (NICE) has produced clinical guidelines (CGs) on the
management of GAD and panic disorder [with or without agoraphobia; (CG113)],48 PTSD (CG26),49 OCD
(CG31)50 and social anxiety disorder (CG159).51 Of the guidelines available, CG113 addresses interventions
for treatment-resistant GAD and CG31 outlines management of OCD that is not responding to treatment,
but neither guideline outlines management of inadequate response to treatment specifically in older
adults. Guidance from NICE advocates a stepped care pathway for GAD,52 panic disorder53 and OCD,54 as
depicted in NICE clinical pathways. By contrast, the pathways for PTSD55 and social anxiety disorder56 are
not based on a series of set treatment phases.
Although treatment strategies are tailored to treat the particular symptoms associated with the needs of
the patient with an anxiety disorder, fundamentally the core principles of the clinical pathways for
recognition and treatment of panic disorders are similar,52–56 with initial steps involving the identification
and assessment of severity of the anxiety disorder. Providing patients with information to understand their
disorder, and the treatment options available, are proposed as an important components of treatment
across anxiety disorders. Evidence from a systematic review indicates that self-help is more effective than
waiting list control in the treatment of anxiety, with a significant reduction in symptoms of anxiety
[standardised mean difference (SMD) −0.86, 95% confidence interval (CI) −1.03 to −0.69 (20 studies,
n= 1121)].57 It should be noted that the evidence in this review is based on a synthesis of data from trials
in various anxiety disorders and moderate statistical heterogeneity (44%) was present.57 Considered
separately, the evidence base for the effectiveness of self-help in the individual anxiety disorders is limited.
TABLE 2 Estimated prevalence of anxiety disorders in older people1
Anxiety disorder Prevalence in older people
GAD 1.2–7.3%
OCD 0.1–0.8%
Social phobia 3.1–10.2%
Specific phobia Not reported
PTSD 0.4–1.0%
Panic disorder 0.1–1.0%
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Self-help, either guided or non-guided, is described in CG113 as a low-intensity psychological treatment
for GAD – these low-intensity psychological interventions listed in CG113 are summarised in Table 3.48
Definition of what constitutes low-intensity psychological therapies varies across studies, but such
interventions are generally those with little or no involvement of a therapist.58 Examples include
bibliotherapy and computer-guided interventions. As contact with a health-care professional is minimal,
low-intensity psychological interventions increase access to psychological treatments for people
experiencing mild to moderate anxiety and depressive disorders.48 Increasing access to psychological
interventions for the treatment of anxiety disorders and depression is a key tenet of the Improving
Access to Psychological Therapies programme, which was launched in the UK in October 2007.59
In GAD, if symptoms of anxiety persist after low-intensity psychological interventions NICE recommends
offering high-intensity psychological interventions as a treatment option.48 People with anxiety disorders
and depression frequently prefer to try psychological interventions before pharmacological agents.
Compared with low-intensity therapies, high-intensity interventions are typically more resource intensive,
involving more contact with appropriately trained health-care professionals; examples of high-intensity
psychological interventions include cognitive–behavioural therapy (CBT) and applied relaxation
(see Table 4). Alternatively, people may be offered a pharmacological treatment if they prefer, with a
selective serotonin reuptake inhibitor (SSRI) typically the first choice for treatment.48 For OCD that is
associated with moderate functional impairment, NICE recommends offering a choice between
higher-intensity CBT or a course of a SSRI as initial treatment.50 Other pharmacological options for anxiety
disorders include a serotonin–noradrenaline reuptake inhibitor (SNRI), pregabalin or a benzodiazepine.
Benzodiazepines have been associated with toxicity, dependence, abuse and cognitive impairment,
and are not recommended for the long-term treatment of anxiety.60
Patients who do not respond to initial psychological or pharmacological treatment, those who are at high
risk of self-harm or neglect, and those suffering from substantial comorbidities might require complex drug
and/or psychological treatment, crisis services, day hospitals or inpatient care.48,50
Guidance on the treatment of anxiety and treatment-resistant anxiety in older adults is lacking. It is well
recognised that anxiety in older people manifests differently from anxiety in younger people. Older people
TABLE 3 Low-intensity interventions for GAD described in NICE CG11348
Intervention Description
Non-facilitated
self-help
Self-administered intervention intended involving a self-help resource (usually a book or workbook)
Similar to guided self-help, but with minimal therapist contact (infrequent telephone call lasting
no longer than 5 minutes)
Guided self-help Self-administered intervention intended to treat symptoms of anxiety
Typically involves a CBT-based self-help resource (e.g. leaflets, books, self-help workbook
or multimedia)
Limited support from a health-care professional: contact between the person and the health-care
professional ranges from 3 to 10 sessions, totalling 3–6 hours of therapy delivered either face to
face or by telephone
Psychoeducational
group
Psychoeducation delivered to a large group (typically 20–24 people)
Focuses on educating people about the nature of anxiety and ways of managing anxiety using
cognitive–behavioural techniques
Weekly sessions led by appropriately trained practitioners (one therapist to 12 group members)
and involving presentations and self-help materials
Sessions typically last for 2 hours and take place over a 6-week period
CBT, cognitive–behavioural therapy.
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are more likely to consult their doctor because of somatic (i.e. physical) or general symptoms (e.g. change
in sleep pattern) rather than concerns about their anxiety.16 As a result, in primary care, older adults are
more likely to be prescribed a benzodiazepine than a SSRI; benzodiazepines are most frequently used to
manage insomnia, particularly in older adults in whom insomnia is caused by anxiety or depression.
The main adverse effects associated with benzodiazepines are sleepiness, unsteadiness and difficulty
with memory and concentration; all of which are more severe in older adults. Benzodiazepines are also
associated with a considerable increase in the risk of falls for an older person.61
Optimising treatment to manage anxiety disorders in older people is complex, and treatment typically
involves a combination of psychotherapy, pharmacotherapy and complementary therapies. Older people
frequently require multiple concomitant treatments to manage comorbid psychological and chronic
medical conditions,1 and are at risk of under-treatment as physicians take care to restrict the number of
medications prescribed. Physiological changes that occur during ageing lead to decreased metabolism and
reduced clearance of pharmacological agents. As a result, older people are at an increased risk of adverse
effects from treatment, a risk that is compounded by increasing the number of drugs administered.62
Additionally, it is well recognised that adherence to treatment among older people can be lower than
among younger adults.1 Lower tolerability for treatment and decline in cognitive function, which is a
natural part of ageing, both contribute to the lower rate of compliance.62 Poor compliance can exacerbate
chronic medical conditions, lead to increased reliance on carers and, ultimately, result in admission to a
residential facility.
Alternative treatment strategies with potential for use in treatment-resistant anxiety include switching
medication and combining pharmacotherapy and psychotherapy, but there is limited evidence evaluating
these treatments. One strategy for which there is a strong evidence base in treating resistant anxiety in a
mixed-age population is augmentation of pharmacotherapy with a second agent. In a review of the
literature, Ipser et al.63 identified 28 randomised controlled trials (RCTs) evaluating the addition of primarily
antipsychotic drugs (17 RCTs) to ongoing pharmacotherapy. Most RCTs evaluated short-term (average
follow-up of 7 weeks) augmentation of a SSRI with an antipsychotic for the treatment of people not
responding to first-line treatment for OCD. Although the findings suggest that this augmentation
approach can be effective in the short term, methodological and clinical heterogeneity among trials
preclude drawing definitive conclusions on effectiveness. Treatment of older people is typically complicated
by issues such as polypharmacy and comorbidity. Physiological functions change with age; for example,
the way in which the body metabolises a drug could differ greatly in older adults compared with younger
adults and, for these reasons, it might be considered inappropriate to extrapolate results from trials
involving a mixed-age sample to older adults. Moreover, because of the additional complexity of
treatment, clinicians in the primary care setting are likely to be cautious about prescribing psychotropic
treatments for older people.
Description of technology under assessment
The interventions under assessment are those that would be used to treat symptoms of anxiety that had
not responded to prior treatment, which, based on NICE guideline CG113 for GAD, would comprise
offering people the choice of either high-intensity psychological treatments or a drug treatment and,
in refractory cases, a combination of psychological and pharmacological treatments;48 guidance on
treatment of persistent anxiety in older people is not available. In the case of GAD that has not responded
to low-intensity psychological interventions, NICE recommends basing choice of treatment on patient
preference as there is no evidence that one mode of treatment (i.e. psychological vs. pharmacological)
is clinically more effective than the other. Based on clinical expert opinion and recommendations for
escalation of treatment in CG113,48 for the review reported here, treatment resistance/refractoriness was
defined as no substantial improvement in symptoms of anxiety, despite treatment with an intervention for
which there is evidence of clinical effectiveness in the treatment of an anxiety disorder.
DOI: 10.3310/hta18500 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 50
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Barton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
High-intensity psychological treatments
High-intensity psychological treatments typically involve one-to-one therapy with a mental health
professional and take place over multiple treatment sessions. High-intensity psychological techniques are
complex and considerably more resource intensive than low-intensity psychological interventions,
comprising multiple components that are typically adapted to an individual; an overview of components of
some high-intensity psychological therapies is presented in Table 4.
Cognitive–behavioural therapy is widely employed in the treatment of anxiety and depression, either on a
one-to-one basis or delivered as part of a group session (see Table 4). CBT has been found to be clinically
beneficial in treating anxiety symptoms associated with GAD,64 panic disorder,65 PTSD,66 social anxiety
disorder67 and OCD.68 Other forms of psychological intervention have been found to offer more benefit in
some disorders than in others. For example, applied relaxation is an alternative to CBT that has benefit
in the treatment of GAD64 and panic disorder65 (see Table 4), and trauma-focused CBT as well as eye
movement desensitisation and reprocessing are used in the treatment of anxiety associated with PTSD49,66
(Table 4). Exposure and response prevention techniques are used in OCD,68 panic disorder65 and social
anxiety disorder.67
Despite evidence that psychological interventions can be effective, older adults generally have reduced
access to such services compared with younger adults. In 2007, it was estimated that 51% of people with
an anxiety disorder in England were not in contact with health-care services and, of those who were in
contact, 46% were not receiving pharmacological or psychological therapy.45 Information focusing on
older adults was not identified. A report from the Older People’s Psychological Therapies Working Group
in Scotland identified that fewer than 10% of older people with depression are referred to specialist
mental health services, compared with 50% of younger adults.69 Moreover, the survey also identified that
80% of older people with depression were not receiving any treatment. A lack of available services was
identified as the largest barrier to older adults receiving high-intensity psychological interventions. The
effectiveness of psychological interventions in older adults with treatment-resistant anxiety is unknown.
Pharmacological treatments
For OCD, social anxiety disorder, GAD and panic disorder, NICE guidance recommends offering a SSRI, in
particular sertraline, as the first pharmacological treatment.48,50,51 Although sertraline is not licensed for the
treatment of GAD, NICE acknowledges that sertraline is clinically effective in treating anxiety disorders and
appears to be the most cost-effective of the SSRIs.48 Alternative pharmacological agents used to treat
symptoms of anxiety are SNRIs, tricyclic antidepressants (TCAs), benzodiazepines (e.g. diazepam), some
anticonvulsants [e.g. pregabalin (Lyrica®, Pfizer)], beta-blockers and other agents with an anxiolytic effect
(e.g. buspirone).70 In addition, augmentation of ongoing pharmacotherapy with an antipsychotic agent
has been found to be clinically effective at improving symptoms of anxiety in treatment-resistant anxiety
disorders.63 However, the effectiveness of these agents in treatment-resistant older adults has not been
evaluated. First-line pharmacological treatment is most likely to be prescribed by a primary care physician.
Clinical trials frequently exclude older adults, and thus there is limited information available on treatment
response in this population.62 Polypharmacy, age-related changes in physiological processes and increased
risk of adverse events, including falls, confusion and depression, present challenges to prescribing
pharmacological agents for older adults. Determination of the appropriate dose for older adults can also
be troublesome. Age-related changes in physiology could lead to increased volume of distribution of the
drug or decreased drug clearance, both of which may result in increased plasma drug concentrations and
adverse effects.62
Selective reuptake inhibitors
Selective serotonin reuptake inhibitors act by selectively inhibiting the reuptake of serotonin
(5-hydroxytryptamine) and SNRIs act by selectively inhibiting the reuptake of noradrenaline and serotonin,
both of which are neurotransmitters. Serotonin is involved in the regulation of mood, sleep and appetite,
and noradrenaline has a role in the body’s response to stress. Dysfunction of the biological pathways
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TABLE 4 High-intensity interventions for anxiety disorders48,49
Intervention Description
CBT Psychotherapeutic approach encompassing various techniques based on
cognitive–behavioural models of disorders. Working with the person with the disorder,
the therapist designs specific techniques that target dysfunctional emotions and
cognitive processes. Treatment goals might include recognising the impact of
behavioural and/or thinking patterns on feeling states and encouraging alternative
cognitive and/or behavioural coping skills
Applied relaxation Focuses on applying muscular relaxation at times of anxiety and facilitates early
response to feelings of anxiety. Applied relaxation is carried out by practitioners of CBT
and sessions are typically weekly, lasting for 12–15 weeks. Components of applied
relaxation include:
l progressive muscle relaxation (focus on particular muscle groups and recognition
of the difference between tensing and relaxing of muscles)
l release-only relaxation (allows the person to enter directly a relaxed state)
l cue-controlled relaxation [reduces the time needed to relax (2–3 minutes) by
generating an association between a cue word and muscle relaxation]
l rapid relaxation (further reduces the time needed to relax by selecting specific cues
that are encountered regularly and practised regularly throughout the day until a
state of deep relaxation can be reached in less than 30 seconds)
l applied relaxation (application of relaxation skills acquired through exposure to
anxiety-provoking situations)
Psychodynamic therapy Focuses on unconscious processes as manifested in a person’s present behaviour
l non-directive treatment with the goals of increasing self-awareness and
understanding of the influence of the past on present behaviour
l process examines unresolved conflicts and symptoms originating from past
conflicts, with a technical focus on interpreting and working though the
dysfunctional situation
Non-directive therapies Psychotherapeutic approach in the person is helped to identify conflicts and to clarify
and understand feelings and values, during which the practitioner does not proffer
advice or interpretation
Trauma-focused CBT Focuses memories, thoughts and feelings that a person has about the traumatic event
Eye movement desensitisation
and reprocessing
Focuses on memories of the traumatic event (including negative thoughts, feelings and
sensations experienced at the time of the event) with the goal of generating more
positive emotions, thoughts and behaviour:
l person focuses on an image connected to the traumatic event and the related
negative emotions, sensations and thoughts, while concentrating on an object
(typically the therapist’s fingers moving from side to side in front of the eyes)
l after each set of eye movements (about 20 seconds), person is encouraged to
discuss the images and emotions experienced during the eye movements
l process is repeated, with a focus on difficult, persisting memories, with
encouragement to have a positive thought about the event
Exposure and
response prevention
Goal is habituation and extinction of responses
l person generates a list of objects/situations that they fear, or avoid, and ranks in
order of decreasing fear (most feared at the top)
l person tackles the object that triggers their anxiety, starting with the least feared
object/situation and working up to the most feared
l repeated daily for > 1 week
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involving serotonin and noradrenaline has long been thought to have a role in the pathogenesis of anxiety
and depression.71 It is thought that SSRIs and SNRIs alleviate symptoms of anxiety and depression by
blocking reuptake and, thus, increasing the levels of serotonin and noradrenaline available. Various SSRIs
and SNRIs have been recommended for the treatment of individual different anxiety disorders;70 anxiety
disorders listed by indication for SSRIs or SNRIs as specified in the British National Formulary (BNF) are
presented in Table 5. Oral doses for the individual SSRIs and SNRIs reported in the BNF are presented
in Appendix 2.
Selective serotonin reuptake inhibitors are the first choice of pharmacological treatment for anxiety
disorders and major depression because they have a better tolerability and adverse effect profile than other
classes of antidepressants.72 In particular, compared with TCAs, the SSRIs do not cause cardiac conduction
abnormalities in overdose and have a low propensity to cause seizures. There are differences in the adverse
effect profiles of the SSRIs, but frequently reported adverse effects include gastrointestinal disturbances
(nausea, vomiting, abdominal pain, diarrhoea and constipation), dry mouth, drowsiness, insomnia, weight
gain and sexual dysfunction.
Caution when prescribing SSRIs is advised for people with epilepsy, cardiac disease, diabetes mellitus,
acute angle-closure glaucoma or those with a history of mania. In addition, caution should be used when
a person has active, or a history of, gastrointestinal bleeding, or is already taking a drug that is associated
with an increased risk of bleeding.60
Benzodiazepines
Benzodiazepines act by enhancing the effect of the neurotransmitter GABA at the GABAA receptor
complex. By increasing the effects of GABA, benzodiazepines induce sedative, hypnotic (sleep-inducing),
anxiolytic, anticonvulsant and muscle-relaxing effects.60 Most benzodiazepines are given orally, but they
can also be administered intravenously, intramuscularly or rectally.60 Examples of benzodiazepines used
as anxiolytics include diazepam, alprazolam, chlordiazepoxide hydrochloride, lorazepam (Ativan®, Valeant)
and oxazepam.
Prescription of benzodiazepines is widespread, but evidence of dependence (physical and psychological)
and tolerance has restricted their usability.60 Benzodiazepines can be effective in alleviating the acute
TABLE 5 Selective reuptake inhibitors used for the treatment of anxiety disorders as specified in the BNF60
Drug
Indication
GAD OCD
Social
anxiety disorder
Specific
phobia PTSD
Panic
disorder
SSRIs
Escitalopram (Cipralex®, Lundbeck) ✓ ✓ ✓ – – ✓
Sertraline (Lustral®, Pfizer) – ✓ ✓ – ✓ ✓
Paroxetine (Seroxat®, GlaxoSmithKline) ✓ ✓ ✓ – ✓ ✓
Citalopram (Cipramil®, Lundbeck) – – – – – ✓
Fluoxetine (Prozac®, Eli Lilly) – ✓ – – – –
Fluvoxamine (Faverin®,
Abbott Healthcare)
– ✓ – – – –
SNRIs
Venlafaxine (Efexor® XL, Pfizer) ✓ – ✓ – – –
Duloxetine (Cymbalta®, Eli Lilly) ✓ – – – – –
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symptoms of severe anxiety in the short term (2–4 weeks), but their use for mild anxiety or chronic
conditions is generally not recommended. In addition, because older adults are at an increased risk of
ataxia and confusion (which in turn increases risk of falling), use of benzodiazepines in older adults is not
recommended. Older adults with an anxiety disorder are most likely to consult their general practitioner
and, in this setting, might be inappropriately prescribed a benzodiazepine as an initial treatment.73 Analysis
of patient records from 131 UK general practices (including approximately 162,000 registered patients
annually aged ≥ 65 years) found that in 2003, benzodiazepines (52.4/1000 people) were one of the most
frequently prescribed potentially inappropriate drugs.73
Tricyclic antidepressants
Originally developed in the 1950s and 1960s, TCAs act by inhibiting the reuptake of serotonin,
noradrenaline and dopamine72 and include drugs such as amitriptyline, clomipramine hydrochloride and
dosulepin hydrochloride.60 Some TCAs inhibit reuptake of serotonin to a greater extent, whereas others
may predominantly block reuptake of noradrenaline. However, most TCAs inhibit reuptake of both
serotonin and noradrenaline. Unlike the SSRIs, the TCAs are non-selective and also interact with additional
receptors and channels, including histamine, cholinergic, adrenergic and dopamine receptors.74 Although
the TCAs are clinically effective in treating anxiety and depression, their interaction with receptors that are
unrelated to depression can lead to the development of often intolerable adverse effects, the most severe
of which involve the cardiovascular system.74 The adverse effect profile of TCAs limits their clinical use.
The BNF lists clomipramine for use in phobic and obsessional states at an initial dose of 25mg daily for
younger adults, and an initial dose of 10mg daily in older adults.60 The dose can be increased over
2 weeks to 100–150mg daily to a maximum of 250mg daily. Older adults are particularly susceptible to
the adverse effects associated with TCAs. A systematic review on the risk of adverse effects associated
with antidepressant use in older adults identified a statistically significant increase in the risk of falls and of
fractures with use of TCAs.75 Initially a low dose should be used and patients should be monitored closely,
particularly checking for psychiatric and cardiac adverse effects.60
Tricyclic antidepressants and related antidepressants should be used with caution in people with
cardiovascular disease, epilepsy, diabetes, and, because of the increased risk of arrhythmias, in people with
concomitant conditions such as hyperthyroidism and phaeochromocytoma.60 The antagonistic action of
TCAs at muscarinic acetylcholine receptors means that caution is also needed when treating people with
prostatic hypertrophy, chronic constipation, increased intraocular pressure or urinary retention or those
with a susceptibility to angle-closure glaucoma. TCAs should be used with caution in people at high risk of
suicide or with a history of psychosis or bipolar disorder; for people with bipolar disorder, treatment with a
TCA should be stopped if the person enters a manic phase.
Antipsychotics
Antipsychotics are used to treat disorders involving psychosis (with symptoms such as delusions and
hallucinations), including schizophrenia and bipolar mania.76 However, the effectiveness of antipsychotics
is not limited to treating psychosis, with evidence of benefit in mood and anxiety disorders, particularly
when used as an adjunctive therapy. Antipsychotics have historically been categorised as first-generation
(also known as typical or conventional) or second-generation (also known as ‘atypical’) antipsychotics,
based on when they were developed;76 examples from the classes listed in the BNF are given in Table 6.60
It is recommended that use of antipsychotics should be limited to the treatment of severe anxiety
symptoms and that they should be used only for short-term treatment.
The first-generation antipsychotics were developed in the 1950s, with second-generation antipsychotics
emerging in the 1980s.76 First- and second-generation antipsychotics both act by blocking dopamine
receptors, but second-generation antipsychotics do so to a lesser extent. Second-generation antipsychotics
also interact with receptors for neurotransmitters other than dopamine, including serotonin and histamine,
and the variation in targeted receptors results in markedly different clinical and adverse effect profiles
within the group.76,77 Choice of treatment is typically determined by medication history and individual risk
of particular side effects, such as weight gain or impaired glucose tolerance. Antipsychotics can be given
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orally or as a depot injection (i.e. antipsychotic injected in a formulation that releases the drug slowly over
a period of time, with injections typically repeated every 2–4 weeks).
When used as an adjunctive treatment for treatment-resistant anxiety or depression, antipsychotics have
predominantly been added to a SSRI (typically fluoxetine).63,78 A systematic review of augmentation of
pharmacotherapy in treatment-resistant anxiety disorders found that augmentation of ongoing therapy
with an antipsychotic significantly reduced symptoms of anxiety in OCD (seven RCTs involving 198 people;
SMD of −0.68, 95% CI −1.13 to −0.24).63
Common adverse effects associated with first-generation antipsychotics include extrapyramidal symptoms
(which involve motor control).76 Compared with second-generation antipsychotics, first-generation
antipsychotics increase the risk of hyperprolactinaemia. By contrast, adverse effects occurring more
frequently with second-generation antipsychotics are weight gain and metabolic abnormalities.76 Among
the second-generation antipsychotics, paliperidone (Invenga®, Janssen Pharmaceuticals) may cause
restlessness and rapid heartbeat, whereas quetiapine is most commonly associated with constipation and
dry mouth. Ziprasidone (Geodon®, Pfizer) and aripiprazole (Abilify®, Otsuka and Bristol-Myers Squibb) are
more likely to be associated with headache, nausea and constipation, but only minor weight gain.
Antipsychotic drugs should be used with caution in people with cardiovascular disease, epilepsy (and
conditions predisposing to seizures), depression, myasthenia gravis, prostatic hypertrophy or a susceptibility
to angle-closure glaucoma.60 Caution is also recommended in severe respiratory disease and in patients
with a history of jaundice or who have blood dyscrasias (perform blood counts if unexplained infection or
fever develops).
TABLE 6 Examples of antipsychotics used as an adjunctive treatment in the management of severe anxiety60
Antipsychotic
Usual daily dose for short-term use in management of
severe anxiety
First-generation antipsychotics
Chlorpromazine 75–300mg
Haloperidol 500 μg twice daily
Pericyazine 15–30mg divided into two doses
Perphenazine 12mg
Prochlorperazine 15–20mg in divided doses
Trifluoperazine 2–4mg in divided doses
Second-generation antipsychoticsa
Amisulpride 50–800mg
Aripiprazole (Abilify®, Otsuka and
Bristol-Myers Squibb)
10–30mg
Clozapine (Clozaril® and FazaClo®,
Novartis Pharmaceuticals)
200–450mg
Olanzapine 10–20mg
Paliperidone (Invenga®, Janssen Pharmaceuticals) 3–12mg
Quetiapine 300–450mg
Risperidone 4–6mg
a Doses specific to short-term management of severe anxiety not reported.
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When prescribing antipsychotics to older adults, the balance of risks and benefits should be considered.60
Antipsychotic drugs have been found to be associated with a small increased risk of mortality and an
increased risk of stroke or transient ischaemic attack in older adults with dementia. When prescribed,
it is recommended that initial doses of antipsychotic drugs for older adults be reduced to half the
recommended adult dose or less (adult doses as listed in the BNF presented in Table 6), and that dosage
could be adjusted further after accounting for individual factors such as weight, comorbidity and
concomitant medication.60
Other drugs used as an anxiolytic
Other drug treatments used to treat the symptoms of anxiety include propranolol (beta-blocker).
pregabalin (anticonvulsant) and buspirone (anxiolytic).
Propranolol is a non-selective beta-blocker, acting by inhibiting the binding of adrenaline and other stress
hormones to the beta adrenoreceptor. Propranolol is primarily used to treat tremor, angina, high blood
pressure, heart rhythm disorders and other heart or circulatory conditions.60 In anxiety disorders
propranolol might be used (typical dose of 40mg once daily) when symptoms such as palpitation,
sweating and tremor are present.60 Common adverse effects associated with propranolol are
gastrointestinal disturbances, low energy, trouble sleeping and feeling weak.
Pregabalin is a structural analogue of GABA but, unlike benzodiazepines, it does not bind directly to GABA
receptors.79 It is thought to elicit an anxiolytic effect through binding to a subunit of voltage-gated calcium
channels in ‘overexcited’ presynaptic neurones in a state-dependent manner, thereby reducing the release
of neurotransmitters, including glutamate and noradrenaline. Pregabalin is licensed for the treatment of
GAD at a starting dose of 150mg in two or three divided doses.60 As with benzodiazepines, there are
concerns about the tolerance of pregabalin during long-term treatment of anxiety disorders and the risk of
symptoms of withdrawal on cessation of treatment.79 Findings from preclinical studies and studies in
healthy volunteers are disparate, and uncertainty remains whether or not the long-term use of pregabalin
might be associated with similar issues observed during prolonged treatment with benzodiazepines.79
Dizziness, drowsiness, dry mouth and constipation are recognised adverse effects when taking pregabalin.
Buspirone is a partial agonist of certain serotonin receptors (i.e. it binds to, and activates, a specific
serotonin receptor, but has only partial efficacy compared with a full agonist).80 Primarily used to treat
GAD, the pharmacological profile of buspirone is different from other anxiolytics in that it alleviates
symptoms of anxiety without the associated effects of sedation or functional impairment. In addition,
the unique profile of buspirone means that use is not associated with dependence or with the risk of
symptoms of withdrawal when treatment is discontinued. The usual dose of buspirone is 15–30mg daily
in divided doses, with a maximum dose of 45mg daily. Common adverse effects of buspirone include
dizziness, headache, drowsiness and nervousness.60
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Chapter 2 Definition of the decision problem
Decision problem
The population of interest is older people (defined as aged ≥ 65 years) who have a primary diagnosis of an
anxiety disorder without a known physical cause and whose symptoms of anxiety have not improved
despite treatment with an intervention for which there is evidence of clinical effectiveness in the treatment
of anxiety.
Pharmacological interventions used for the treatment of anxiety disorders were evaluated in the review and
were not restricted to those licensed in Europe. Additionally, psychological and alternative therapies were
also considered. Interventions were eligible when given as a monotherapy or in combination with another
intervention for the treatment of anxiety. Interventions were compared with each other, both as a
monotherapy and in combination with another intervention.
The primary outcome of interest is a reduction in symptoms of anxiety as determined by a validated
disease-specific outcome measure: dichotomous and continuous measures of response to treatment
were to be reported. A clinically meaningful improvement in response would be determined by the
outcome measure used.
Secondary outcomes of interest are:
l response (defined as proportion of people experiencing ≥ 50% reduction in symptom score
from baseline)
l remission (as defined in the individual studies)
l functional disability (encompasses effect on work, social interaction and family life)
l sleep quality
l development of, or change in, symptoms of depression
l adherence to treatment
l QoL
l carer outcomes (including carers’ well-being, experience of care-giving and carers’ needs for
professional support)
l adverse effects (all-cause for any identified intervention).
Key issues
Treatment-resistant anxiety disorders have been the focus of numerous RCTs. Despite the burgeoning
research in this field, as in treatment-resistant depression, criteria for treatment resistance and response
and remission vary across studies, with some studies not reporting clear criteria. RCTs have defined
resistance as inadequate response to treatment, but with no further detail on what would be classed as an
inadequate response. As in treatment-resistant depression, treatment resistance in anxiety disorders has
also been determined by no response after treatment with at least two antidepressants at adequate
doses.81–85 Again, studies vary in the required duration and adequate dosage of standard treatment. As
noted earlier, categorisation of treatment resistance in anxiety disorders is further complicated by the
nature of the disorders. Reduction in severity of symptoms does not necessarily denote response to
treatment, and continued anxiety after treatment could suggest inadequate initial treatment or a natural
transient reaction to a supervening stress factor rather than non-response. Variation in the criteria used
across studies, and the complexity associated with evaluating anxiety disorders, contribute to the difficulty
in interpreting the comparative clinical effectiveness of treatments from the limited evidence available.
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It has been noted that populations enrolled across clinical trials evaluating treatments for older adults with
anxiety disorders have not been, in the main, representative of older adults in general, in terms of age,
functional status, ethnicity or medical health.3 People enrolled in clinical trials are relatively homogeneous,
having a specific disorder and few or no comorbidities, which does not perhaps represent older adults in
general who typically have several comorbid physical or mental health illnesses.86 Also, most trials have
been carried out in an academic setting, with set treatment guides and set follow-up, which is atypical of
the setting in which most older adults would receive care for their anxiety disorder.
Overall aims and objectives of assessment
The aim of the report was to evaluate the clinical effectiveness of medical, psychological and alternative
therapies for treatment-resistant anxiety in older people. The lack of data assessing interventions in older
people with treatment-resistant anxiety precluded achievement of the aim of the report. Potential areas
for further research in the clinical area are outlined in Chapter 3 (Assessment of clinical effectiveness).
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Chapter 3 Assessment of clinical effectiveness
Methods for reviewing effectiveness
The aim of the systematic review was to evaluate the clinical effectiveness of any intervention
(i.e. pharmacological, psychological or alternative) used to treat anxiety, in older adults with a focus
on the treatment of anxiety that had not improved after treatment with an intervention for which there
is evidence of clinical effectiveness in treating anxiety. Evidence was assessed by conducting a systematic
review of the published research literature. The review was undertaken following the general principles
published by the Centre for Reviews and Dissemination (CRD).87 The protocol for the systematic review is
registered on PROSPERO (registration number CRD42013005612).88
Identification of studies
Search strategies were designed to include medical subject headings (MeSH) and text terms for anxiety
disorders (both as a collective term and as individual anxiety disorders), treatment failure and older adults.
To maximise the number of potentially relevant studies retrieved, no MeSH or text terms were included for
interventions of interest. Based on the results of the initial scoping search, it was anticipated that few RCTs
that focused on older adults would be identified, despite the large number of studies retrieved. Therefore,
the decision was taken to search additionally for prospective observational studies (matched control
studies, case series and case–control studies). Search filters based on study design were identified via the
InterTASC Information Specialists’ Sub-Group search filter resource.89 Filters developed and validated by the
Scottish Intercollegiate Guidelines Network (SIGN) were used to identify RCTs in MEDLINE and EMBASE.90
Filters devised by Clinical Evidence (a collection of systematic overviews covering various conditions) were
chosen to retrieve potentially relevant observational studies from MEDLINE and EMBASE.91 For the search
of PsycINFO, filters implemented for study type were those designed by the University of Texas School of
Public Health to retrieve RCTs and observational studies.92 Search terms for anxiety, treatment resistance
and older adults were tailored to the database searched. Bibliographies of previous reviews and retrieved
articles were searched for additional studies. A clinical trial registry (ClinicalTrials.gov) was also searched to
identify planned, on-going and finalised clinical trials of interest. In addition, clinical experts were contacted
with a request for information on any additional studies of which they had knowledge. Conference
abstracts that were reviewed and found not to report additional results to those presented in the relevant
full publication were excluded.
The electronic databases searched were:
l MEDLINE In-Process & Other Non-Indexed Citations and Ovid MEDLINE
l EMBASE
l The Cochrane Library [specifically Cochrane Database of Systematic Reviews, Cochrane Central Register
of Controlled Trials (CENTRAL), Database of Abstracts of Reviews and Effects, and Health Technology
Assessment Database]
l PsycINFO
l Web of Science.
Databases were searched from inception to September 2013 with the exception of Web of Science, and the
initial search was carried out on 9 September 2013. Search parameters for Web of Science were limited to a
search period of 2000–present, with study type restricted to article, meeting abstract, proceedings paper and
corrections. Search results were uploaded into Reference Manager Version 11.0 (Thomson ResearchSoft,
San Francisco, CA, USA) and deduplicated. Full details of the strategies are presented in Appendix 3.
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Titles and abstracts returned by the search strategy were examined independently by two researchers
[Charlotta Karner (CK) and Fatima Salih (FS)] and screened for possible inclusion. In cases where consensus
could not be achieved, the full text of potentially relevant studies was ordered. During abstract appraisal,
to facilitate discussion regarding whether or not sufficient evidence had been identified to restrict inclusion
of study type to RCTs, potentially relevant studies were categorised as RCT, observational study or
systematic review. To ensure that all relevant data were evaluated for inclusion, studies were not
differentiated during appraisal of titles and abstracts based on age of the population, to allow for potential
reporting of analysis of subgroups by age within the full text.
Full publications were assessed independently by two reviewers [Samantha Barton (SB) and CK] for
inclusion or exclusion against prespecified criteria, with studies classified as a RCT evaluated first. After
appraisal of full-text publications, the lack of RCTs meeting the prespecified inclusion criteria led to the
evaluation of prospective observational studies for inclusion in the review. Disagreements on inclusion of
a study, and on which consensus could not be reached, were resolved by discussion or input from a third
reviewer [Steven J Edwards (SJE)].
Inclusion and exclusion criteria
Inclusion criteria were based on the decision problem outlined in Chapter 2, Decision problem (presented
in Table 7). No restrictions were imposed on language of publication. Reference lists of identified
systematic reviews were used as a source of potential additional studies, as well as a resource to compare
studies retrieved from the systematic literature search. For the purposes of this review, a systematic review
was defined as review reporting:
l a focused research question
l details of the search strategy, including databases searched and terms used, that would enable
replication of the search
l inclusion/exclusion criteria, with clear definitions for population, intervention(s), comparator(s) and
outcome(s) of interest
l critical appraisal of included studies.
Studies not meeting the prespecified inclusion criteria were excluded and studies specifying an age range
as an inclusion criterion, and in which the upper age limit was 65 years, were excluded. Studies were also
excluded if they were:
l trials reporting only post-crossover results and pre-crossover results could not be obtained
l case reports, historical articles, narrative reviews, editorials and opinion pieces
l reports published as only meeting abstracts and where insufficient methodological details were
reported to allow critical appraisal of study quality.
Where it was not possible to determine the age of the included population (e.g. baseline characteristics
not reported), authors were contacted with a request for additional information. No additional information
was provided within the prespecified deadline for return of comments (1 month).
Planned data abstraction, critical appraisal, subgroup analyses and evidence synthesis procedures are
documented in the review protocol.
Results of the review of clinical effectiveness evidence
No study, either RCT or observational, meeting the prespecified inclusion criteria was identified. The search
of clinical trial registries identified no ongoing or planned RCTs in older adults with a treatment-resistant
anxiety disorder. The emergence of systematic reviews evaluating the clinical effectiveness of
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pharmacological and psychological treatments for anxiety in older adults highlights the increasing
awareness of the need to manage this condition.3,93,94
Quantity and quality of research available
The searches retrieved a total of 3644 records (post deduplication) that were of possible relevance to
the review (Figure 1). These were screened and 109 full references were ordered. Of the full references
evaluated, the full publication of only one study was not obtained.95 No study met the prespecified
inclusion criteria outlined in Table 7.
The full list of studies screened and subsequently excluded (with reasons for exclusion) from the review is
presented in Appendix 4.
TABLE 7 Inclusion criteria
PICO Criteria
Population People aged ≥ 65 years with a primary diagnosis of an anxiety disorder and who are resistant/
refractory to treatment
Anxiety and
related disorders
Anxiety disorders specified as:
l GAD
l panic disorder (with or without agoraphobia)
l social phobia (social anxiety disorder)
l specific (simple phobia)
l OCD
l PTSD
Treatment resistance Defined as no evidence of substantial improvement after 4 weeks’ treatment with a treatment for
which there is evidence of clinical effectiveness in the treatment of anxiety
Interventions Any intervention (psychological, pharmacological or alternative) used to treat treatment-resistant
anxiety. Interventions given alone or in combination (e.g. combination of psychological plus
pharmacological interventions) would be included
Comparators Any intervention versus placebo, no intervention (e.g. waiting list control) or another active
intervention (including interventions given alone or in combination)
Outcomes Primary outcomes:
l reduction in symptoms of anxiety as determined by a validated disease-specific outcome
measure (dichotomous and continuous measures of response to treatment will be included)
Secondary outcomes:
l response: defined as the proportion of people experiencing ≥ 50% reduction in symptom
score from baseline
l remission: defined as in the individual studies
l functional disability (encompasses effect on work, social interaction and family life)
l sleep quality
l development of, or change in, symptoms of depression
l adherence to treatment
l QoL
l carer outcomes (including carers’ well-being, experience of care-giving and carers’ needs for
professional support)
l adverse effects (all-cause for any identified intervention)
Study design RCTs and comparative observational studies (prospective matched control studies, case series and
case–control studies)
Other criteria No restrictions on language or date of publication
PICO, population, intervention, comparator and outcome.
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Assessment of effectiveness
No study was identified that evaluated clinical effectiveness of interventions for treatment-resistant anxiety
in older adults. Older adults present with manifestations of anxiety different from those of younger adults.
Taken together with the finding that response to treatment is poorer in later life,96 it might be that results
from studies in younger adults with anxiety disorders cannot be applied to older adults. Considering
treatment of anxiety disorders in older adults, systematic reviews of interventions for the treatment of
anxiety in later life have found that psychological93,97 and pharmacological94 treatments are effective in
reducing symptoms of anxiety in this population, with the authors of one review commenting that
evidence is strongest for the treatment of GAD.3 However, it has been noted that the studies identified by
the reviews were small, with an average of 16 people and 43 people in these studies evaluating
psychological and pharmacological treatments, respectively.98 Although there is an increasing awareness of
the difficulties in treating anxiety in older adults, there is a lack of an evidence base in this population.98
Records after duplicates removed
(n = 3644)
Records identified through database
searching (n = 4810)
• The Cochrane Library, n = 931
• EMBASE, n = 1116
• MEDLINE, n = 1209
• PsycINFO, n = 299
• Web of Science, n = 1255
Additional records identified
from other sources
reference lists of
systematic reviews
 (n = 4)
Records excluded after
abstract and title appraisal
(n = 3535)
Reasons for exclusion
• Not study type of interest, n = 15
• Not question of interest, n = 1
• Not population of interest, n = 47
• No subgroup by age, n = 41
• Baseline characteristics not
   available or insufficient
   information reported, n = 4
• Unable to obtain, n = 1 
Full-text articles assessed
for eligibility
(n = 109)
Studies included meeting a priori
pre-specified inclusion criteria
(n = 0)
Full-text articles excluded
(n = 109)
FIGURE 1 PRISMA flow diagram for studies included and excluded from the clinical effectiveness review.
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Chapter 4 Discussion
Statement of principal findings
This systematic review has highlighted the lack of an evidence base for the treatment of older adults with
an anxiety disorder that have not responded, or has responded inadequately, to prior treatment. Although
multiple RCTs were identified that evaluated clinical effectiveness of interventions for treatment-resistant
anxiety disorders, many limited inclusion to adults aged 65 years and under. Of those studies that included
people aged over 65 years, the mean ages reported at baseline suggest that most included people were
younger than 65 years. The potentially small number of people likely to be aged 65 and over in the studies
identified restricts the practicality and feasibility of carrying out a meta-analysis based on individual patient
data. In addition, as the studies identified evaluated a range of treatments across various anxiety disorders,
it is likely that the number of events for each treatment would be low, which would probably lead to
considerable uncertainty in the results.
Strengths and limitations of the assessment
The review reported here is the first systematic review of interventions for treatment-resistant anxiety in
older adults. The comprehensive methods implemented to carry out the review are a key strength of the
research presented. However, the review highlights the lack of research in this area, identifying no
comparative studies, which is a limitation.
Uncertainties
As no study was identified in older adults, there is considerable uncertainty as to which interventions might
be clinically effective for older adults with an anxiety disorder that has not responded, or has responded
inadequately, to prior treatment. Disparity between older and younger adults in the presentation of anxiety
symptoms and in response to treatment could mean that results demonstrating the clinical effectiveness of
interventions in treatment-resistant anxiety disorders in younger adults cannot necessarily be applied to
older adults with comparable anxiety disorders.
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Chapter 5 Conclusions
Implications for service provision
Identification and treatment of mental disorders is complex, and consideration of the needs and
preferences of an individual is advocated when considering treatment choice. The review reported here
supports conclusions from other studies that, at this time, the further management of treatment-resistant
anxiety disorders in older adults cannot be guided by evidence from meta-analysis or RCTs. In older adults
a common underlying reticence to discuss emotional symptoms, together with the misconception that
anxiety is a natural part of the ageing process, means that older adults typically receive poorer mental
health care than younger adults. The lack of high-level evidence in this area means that older adults are
perhaps receiving inappropriate treatment or are not receiving a particular treatment because there is little
evidence to support its use. At this time, there is scope to develop guidance on service provision and, as a
consequence, to advance the standard of care received by older adults with an anxiety disorder in the
primary and secondary settings.
Suggested research priorities
Studies evaluating interventions in older adults with an anxiety disorder that has not responded to first-line
treatment are needed to address the lack of evidence in this clinical area. An important consideration
would be the enrolment of older adults who would be representative of older adults in general, i.e. those
with multiple comorbid physical and mental disorders that might require polypharmacy. In addition, it
would be important to consider the setting in which the study was carried out to reflect the setting in
which treatment is typically administered. In those taking multiple pharmacological agents, the properties
of a particular drug could change considerably, leading to unexpected adverse effects as well as clinical
effects. Therefore, assessment of adverse effects could be of equal importance to evaluation of
clinical effectiveness.
Randomised controlled trials in anxiety disorders have often involved a heterogeneous population in terms
of anxiety disorder, enrolling people with any form of anxiety disorder. As noted earlier, the different types
of anxiety disorder respond to differing treatments and to varying degrees. Focusing on a particular
anxiety disorder would be important to discern the most effective treatment for that disorder. However,
acknowledged difficulties in defining and identifying treatment resistance in older adults could result in
poor recruitment, both in terms of the low number of older adults likely to be categorised as treatment
resistant and the heterogeneity in terms of prior treatment.
Anxiety disorders are typically chronic or episodic conditions, and maintaining an initial response is a key
goal of treatment. Longitudinal studies that examine relapse or recurrence rates would provide an
impression of the long-term effectiveness and acceptability of treatment interventions.
Given the often multiple drug treatment regimens taken by older adults, a focus on research into
non-pharmacological treatments might be useful, building on currently implemented psychological
therapies such as CBT. From the patient’s perspective, developing uncomplicated, undemanding
interventions that can be delivered at home or in groups might be warranted. Physical frailty, which is
common in older adults, might preclude older adults from accessing services that are some distance from
their home.
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Difficulties encountered when undertaking RCTs in older adults include the perceptions of health
professionals and practical problems relating to attending for regular assessments.99 From the patient
perspective, older adults have expressed fear of trial treatment and a dislike of the randomisation
process.1,3,99 Issues with transport, time taken to be involved in the trial and concerns about compromising
current care are also barriers, generally, to patient participation in a clinical trial.99 To overcome these
potential barriers, a prospective matched control observational study might be an appropriate study design.
In summary, studies focusing on a specific anxiety disorder in older adults who have not responded, or
have made an inadequate response, to prior treatment are warranted, with a suggested initial focus on
effectiveness of non-pharmacological treatments. Given the epidemiological evidence that GAD is the most
common anxiety disorder affecting older adults, initial studies evaluating treatments for this disorder might
give greatest clinical benefit to a wider population base. Furthermore, the typically chronic nature of
anxiety disorders is such that longitudinal studies to monitor maintenance of treatment effect would be
needed to provide an insight into the long-term effectiveness and acceptability of treatments.
CONCLUSIONS
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Appendix 1 Diagnostic criteria for anxiety
disorders set out in DSM-IV and ICD-10
classification systems
DSM-IV diagnostic criteria9,100 ICD-10 diagnostic criteria11
GAD
A. Excessive anxiety and worry (apprehensive expectation),
occurring on more days than not for at least 6 months,
about a number of events or activities (such as work or
school performance)
A. A period of at least six months with prominent tension,
worry and feelings of apprehension, about every-day
events and problems
B. The person finds it difficult to control the worry B. At least four symptoms out of the following list of items
must be present, of which at least one from items 1 to 4
Autonomic arousal symptoms
1. palpitations or pounding heart, or accelerated
heart rate
2. sweating
3. trembling or shaking
4. dry mouth (not owing to medication or dehydration)
Symptoms concerning chest and abdomen
5. difficulty breathing
6. feeling of choking
7. chest pain or discomfort
8. nausea or abdominal distress (e.g. churning in stomach)
Symptoms concerning brain and mind
9. feeling dizzy, unsteady, faint or light-headed
10. feelings that objects are unreal (derealisation), or that
one’s self is distant or ‘not really
here’ (depersonalisation)
11. fear of losing control, going crazy or passing out
12. fear of dying
General symptoms
13. hot flushes or cold chills
14. numbness or tingling sensations
Symptoms of tension
15. muscle tension, or aches and pains
16. restlessness and inability to relax
17. feeling keyed up, or on edge, or of mental tension
18. a sensation of a lump in the throat, or difficulty with
swallowing
Other non-specific symptoms
19. exaggerated response to minor surprises or
being startled
20. difficulty in concentrating, or mind going blank,
because of worrying or anxiety
21. persistent irritability
22. difficulty getting to sleep because of worrying
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DSM-IV diagnostic criteria9,100 ICD-10 diagnostic criteria11
C. The anxiety and worry are associated with three
(or more) of the following six symptoms (with at least some
symptoms present for more days than not for the past
6 months). Note that only one item is required in children
1. Restlessness or feeling keyed up or on edge
2. Being easily fatigued
3. Difficulty concentrating or mind going blank
4. Irritability
5. Muscle tension
6. sleep disturbance (difficulty falling or staying asleep,
or restless unsatisfying sleep)
C. The disorder does not meet the criteria for panic
disorder, phobic anxiety disorders, obsessive–compulsive
disorder or hypochondriacal disorder
D. The focus of the anxiety and worry is not confined to
features of an Axis I disorder, e.g. the anxiety or worry is
not about having a panic attack (as in panic disorder),
being embarrassed in public (as in social phobia), being
contaminated (as in obsessive–compulsive disorder),
being away from home or close relatives (as in
separation anxiety disorder), gaining weight (as in
anorexia nervosa), having multiple physical complaints
(as in somatization disorder), or having a serious illness
(as in hypochondriasis), and the anxiety and worry do
not occur exclusively during PTSD
D. Most commonly used exclusion criteria: not sustained by a
physical disorder, such as hyperthyroidism, an organic
mental disorder or psychoactive substance-related disorder,
such as excess consumption of amphetamine-like
substances, or withdrawal from benzodiazepines
E. The anxiety, worry or physical symptoms cause clinically
significant distress or impairment in social, occupational
or other important areas of functioning
F. The disturbance is not caused by the direct physiological
effects of a substance (e.g. a drug of abuse, a
medication) or a general medical condition
(e.g. hyperthyroidism) and does not occur exclusively
during a mood disorder, a psychotic disorder, or a
pervasive developmental disorder
Obsessive–compulsive disorder
A. Either obsessions or compulsions:
Obsessions as defined by (1), (2), (3) and (4):
1. recurrent and persistent thoughts, impulses or images
that are experienced, at some time during the
disturbance, as intrusive and inappropriate, and that
cause marked anxiety or distress
2. the thoughts, impulses or images are not simply
excessive worries about real-life problems
3. the person attempts to ignore or suppress such
thoughts, impulses or images, or to neutralise them with
some other thought or action
4. the person recognises that the obsessional thoughts,
impulses or images are a product of his or her own mind
(not imposed from without as in thought insertion)
Compulsions as defined by (1) and (2):
1. Repetitive behaviours (e.g. hand washing, ordering,
checking) or mental acts (e.g. praying, counting,
repeating words silently) that the person feels driven to
perform in response to an obsession, or according to
rules that must be applied rigidly
2. The behaviours or mental acts are aimed at preventing
or reducing distress, or preventing some dreaded event
or situation. However, these behaviours or mental acts
either are not connected in a realistic way with what
they are designed to neutralise or prevent, or are
clearly excessive
A. Either obsessions or compulsions (or both), present on
most days for a period of at least 2 weeks
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DSM-IV diagnostic criteria9,100 ICD-10 diagnostic criteria11
B. At some point during the course of the disorder
the person has recognised that the obsessions or
compulsions are excessive or unreasonable. Note
that this does not apply to children
B. Obsessions (thoughts, ideas or images) and compulsions
(acts) share the following features, all of which must be
present:
1. they are acknowledged as originating in the mind of
the patient and are not imposed by outside persons
or influences
2. they are repetitive and unpleasant, and at least one
obsession or compulsion must be present that is
acknowledged as excessive or unreasonable
3. the subject tries to resist them (but if very long-
standing, resistance to some obsessions or
compulsions may be minimal). At least one obsession
or compulsion must be present that is
unsuccessfully resisted
4. carrying out the obsessive thought or compulsive act is
not in itself pleasurable (this should be distinguished
from the temporary relief of tension or anxiety)
C. The obsessions or compulsions cause marked distress,
are time-consuming (take more than 1 hour a day, or
significantly interfere with the person’s normal routine,
occupational (or academic) functioning or usual social
activities or relationships
C. The obsessions or compulsions cause distress or interfere
with the subject’s social or individual functioning, usually
by wasting time.
D. If another Axis I disorder is present, the content of the
obsessions or compulsions is not restricted to it (e.g.
preoccupation with food in the presence of an eating
disorder; hair pulling in the presence of trichotillomania;
concern with appearance in the presence of body
dysmorphic disorder; preoccupation with drugs in the
presence of a substance use disorder; preoccupation
with having a serious illness in the presence of
hypochondriasis; preoccupation with sexual urges or
fantasies in the presence of a paraphilia; or guilty
ruminations in the presence of major depressive disorder)
D. Most commonly used exclusion criteria: not caused by
other mental disorders, such as schizophrenia and
related disorders, or mood (affective) disorders
E. The disturbance is not caused by the direct physiological
effects of a substance (e.g. a drug of abuse, a
medication) or a general medical condition
Panic disordera
A. Both (1) and (2):
i. recurrent unexpected panic attacks
ii. at least one of the attacks has been followed by 1
month (or more) of one (or more) of the following:
iii. persistent concern about having additional attacks
iv. worry about the implications of the attack or its
consequences (e.g. losing control, having a heart
attack, ‘going crazy’)
v. a significant change in behaviour related to
the attacks
A. Recurrent panic attacks that are not consistently
associated with a specific situation or object and often
occurring spontaneously (i.e. the episodes are
unpredictable). The panic attacks are not associated with
marked exertion or with exposure to dangerous or
life-threatening situations
B. Absence of agoraphobia/presence of agoraphobia B. A panic attack is characterised by all of the following:
(a) it is a discrete episode of intense fear or discomfort
(b) it starts abruptly
(c) it reaches a crescendo within a few minutes and lasts
at least some minutes
(d) at least four symptoms must be present from the list
below, one of which must be from items 1 to 4:
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DSM-IV diagnostic criteria9,100 ICD-10 diagnostic criteria11
Autonomic arousal symptoms
1. palpitations or pounding heart, or accelerated
heart rate
2. sweating
3. trembling or shaking
4. dry mouth (not caused by medication or dehydration)
Symptoms concerning chest and abdomen
5. difficulty breathing
6. feeling of choking
7. chest pain or discomfort
8. nausea or abdominal distress (e.g. churning in stomach)
Symptoms concerning brain and mind
9. feeling dizzy, unsteady, faint or light-headed
10. feelings that objects are unreal (derealisation),
or that one’s self is distant or ‘not really
here’ (depersonalisation)
11. fear of losing control, going crazy or passing out
12. fear of dying
General symptoms
13. hot flushes or cold chills
14. numbness or tingling sensations
C. The panic attacks are not caused by the direct
physiological effects of a substance (e.g. a drug of
abuse, a medication) or a general medical condition
(e.g. hyperthyroidism)
C. Most commonly used exclusion criteria: not caused by a
physical disorder, organic mental disorder, or other
mental disorder such as schizophrenia and related
disorders, affective disorders or somatoform disorders
D. The panic attacks are not better accounted for by
another mental disorder, such as social phobia
(e.g. occurring on exposure to feared social situations),
specific phobia (e.g. exposure to a specific phobic
situation), OCD (e.g. on exposure to dirt in someone
with an obsession about contamination), PTSD (e.g. in
response to stimuli associated with a severe stressor) or
separation anxiety disorder (e.g. in response to being
away from home or close relatives)
PTSD
A. The person has been exposed to a traumatic event in
which both of the following were present:
1. the person experienced, witnessed, or was confronted
with an event, or events, that involved actual or
threatened death or serious injury, or a threat to the
physical integrity of self or others
2. the person’s response involved intense fear,
helplessness or horror. Note that in children this may
be expressed instead by disorganised or
agitated behaviour
A. Exposure to a stressful event or situation (either short or
long lasting) of exceptionally threatening or catastrophic
nature, which is likely to cause pervasive distress in
almost anyone
B. The traumatic event is persistently re-experienced in one
(or more) of the following ways:
1. recurrent and intrusive distressing recollections of the
event, including images, thoughts or perceptions. Note
that in young children repetitive play may occur in
which themes or aspects of the trauma are expressed
B. Persistent remembering or ‘reliving’ the stressor by
intrusive flash backs, vivid memories, recurring dreams or
by experiencing distress when exposed to circumstances
resembling or associated with the stressor
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DSM-IV diagnostic criteria9,100 ICD-10 diagnostic criteria11
2. recurrent distressing dreams of the event. Note that in
children these may be frightening dreams without
recognisable content
3. acting or feeling as if the traumatic event were
recurring (includes a sense of reliving the experience,
illusions, hallucinations and dissociative flashback
episodes, including those that occur on awakening or
when intoxicated). Note that in young children
trauma-specific re-enactment may occur
4. intense psychological distress at exposure to internal
or external cues that symbolise or resemble an aspect
of the traumatic event; physiological reactivity on
exposure to internal or external cues that symbolise or
resemble an aspect of the event
C. Persistent avoidance of stimuli associated with the
trauma and numbing of general responsiveness
(not present before the trauma), as indicated by three
(or more) of the following:
1. efforts to avoid thoughts, feelings or conversations
associated with the trauma
2. efforts to avoid activities, places or people who arouse
recollections of the trauma
3. inability to recall an important aspect of the trauma
4. markedly diminished interest or participation in
significant activities
5. feeling of detachment or estrangement from others
6. restricted range of affect (e.g. unable to have
loving feelings)
7. sense of a foreshortened future (e.g. does not expect
to have a career, marriage, children or a normal
life span)
C. Actual or preferred avoidance of circumstances
resembling, or associated with, the stressor (not present
before exposure to the stressor)
D. Persistent symptoms of increased arousal (not present
before the trauma), as indicated by two (or more) of
the following:
i. difficulty falling or staying asleep
ii. irritability or outbursts of anger
iii. difficulty concentrating
iv. hypervigilance
v. exaggerated startle response
D. Either (1) or (2):
1. inability to recall, either partially or completely, some
important aspects of the period of exposure to
the stressor
2. persistent symptoms of increased psychological
sensitivity and arousal (not present before exposure to
the stressor), shown by any two of the following:
i. difficulty in falling or staying asleep
ii. irritability or outbursts of anger
iii. difficulty in concentrating
iv. hypervigilance
v. exaggerated startle response
E. Duration of the disturbance (symptoms in Criteria B, C
and D) is more than 1 month
E. Criteria B, C and D all occurred within six months of the
stressful event or the end of a period of stress (for some
purposes, onset delayed more than six months may be
included but this should be clearly specified separately)F. The disturbance causes clinically significant distress or
impairment in social, occupational or other important
areas of functioning
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DSM-IV diagnostic criteria9,100 ICD-10 diagnostic criteria11
Social anxiety disorder
A. A marked and persistent fear of one or more social or
performance situations in which the person is exposed
to unfamiliar people or to possible scrutiny by others.
The individual fears that he or she will act in a way
(or show anxiety symptoms) that will be humiliating or
embarrassing. Note: in children, there must be evidence
of the capacity for age-appropriate social relationships
with familiar people and the anxiety must occur in peer
settings, not just interactions with adults
A. Either (1) or (2):
1. marked fear of being the focus of attention or fear of
behaving in a way that will be embarrassing
or humiliating
2. marked avoidance of being the focus of attention or
situations in which there is fear of behaving in an
embarrassing or humiliating way
These fears are manifested in social situations, such as
eating or speaking in public; encountering known
individuals in public; or entering or enduring small group
situations, such as parties, meetings and classrooms
B. Exposure to the feared social situation almost invariably
provokes anxiety, which may take the form of a
situationally bound or situationally predisposed Panic
attack. Note: in children, the anxiety may be expressed by
crying, tantrums, freezing, or shrinking from social
situations with unfamiliar people
B. At least two symptoms of anxiety in the feared situation
at some time since the onset of the disorder, as defined
in criterion B for agoraphobia and in addition one of the
following symptoms:
1. blushing
2. fear of vomiting
3. urgency or fear of micturition or defaecation
C. The person recognises that the fear is excessive or
unreasonable. Note: in children, this feature may
be absent
C. Significant emotional distress caused by the symptoms or
by the avoidance
D. The feared social or performance situations are avoided
or else are endured with intense anxiety or distress
D. Recognition that the symptoms or the avoidance are
excessive or unreasonable
E. The avoidance, anxious anticipation, or distress in the
feared social or performance situation(s) interferes
significantly with the person’s normal routine,
occupational (academic) functioning, or social activities or
relationships, or there is marked distress about having
the phobia
E. Symptoms are restricted to, or predominate in, the feared
situation or when thinking about it
F. In individuals under age 18 years, the duration is at least
6 months
F. Most commonly used exclusion criteria: Criteria A and B
are not caused by delusions, hallucinations or other
symptoms of disorders such as organic mental disorders,
schizophrenia and related disorders, affective disorders or
OCD, and are not secondary to cultural beliefs
G. The fear or avoidance is not due to the direct
physiological effects of a substance (e.g., a drug of
abuse, a medication) or a general medical condition and
is not better accounted for by another mental disorder
(e.g., panic disorder with or without agoraphobia,
separation anxiety, body dysmorphic disorder, a pervasive
developmental disorder, or schizoid personality disorder)
H. If a general medical condition or another mental disorder
is present, the fear in Criterion A is unrelated to it,
e.g. the fear is not of stuttering, trembling in Parkinson’s
disease, or exhibiting abnormal eating behaviour in
anorexia nervosa
a The DSM-IV distinguishes panic disorder with agoraphobia from panic disorder without agoraphobia; as indicated by
criterion B under the heading of panic disorder.
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Appendix 2 Doses of selective reuptake
inhibitors for individual anxiety disorders as
listed in the British National Formulary60
Drug Brand name Manufacturer Dose
SSRIs
Escitalopram Cipralex® H. Lundbeck A/S GAD and OCD
l 10mg once daily, increased to a maximum of 20mg daily,
if required
l older adults: initially half adult dose and a maximum of 10mg daily
Panic disorder, with or without agoraphobia
l initial dose of 5mg for the first week before increasing the dose to
10mg daily. Dose can be further increased up to a maximum of
20mg daily
l older adults: initially half adult dose, and a maximum of
10mg daily
Social anxiety disorder
l 10mg once daily, adjusted after 2–4 weeks. Usual dose of
5–20mg daily, dependent on response
l older adults: not recommended
Sertraline
(unlicensed)
Lustral® Pfizer Panic disorder, with or without agoraphobia, social anxiety disorder
and PTSD
l initially 25mg daily, increased after 1 week to 50mg daily; if
response is partial and if drug tolerated, dose increased in steps of
50mg at intervals of at least 1 week to a maximum of
200mg daily
OCD
l adult and child over 12 years initially 50mg daily, increased if
necessary in steps of 50mg at intervals of at least 1 week to a
maximum dose of 200mg daily
Paroxetine Seroxat® GlaxoSmithKline Social anxiety disorder, PTSD and GAD
l recommended dose 20mg each morning to a maximum dose of
50mg daily
l older adult: as above, but to a maximum dose of 40mg daily
OCD
l initially 20mg each morning, increased gradually in steps of 10mg
to recommended dose of 40mg daily. Maximum dose of
60mg daily
l older adult: as above, but to a maximum dose of 40mg daily
Panic disorder
l initially 10mg each morning, increased gradually in steps of 10mg
to recommended dose of 40mg daily. Maximum dose of
60mg daily
l older adult: as above, but to a maximum dose of 40mg daily
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Drug Brand name Manufacturer Dose
Citalopram Cipramil® Lundbeck Panic disorder
l 10mg daily, increased gradually if necessary in steps of 10mg
daily, usual dose 20–30mg daily. Maximum dose of 40mg daily
l older adult: as above, but to a maximum dose of 20mg daily
Fluoxetine Prozac® Lilly OCD
l 20mg daily, increased gradually if necessary to a maximum of
60mg daily
l older adults: as above, but maximum dose is typically 40mg daily,
but 60mg can be used
Fluvoxamine Faverin® Abbott
Healthcare
OCD
l initially 50mg in the evening, increased gradually if necessary after
some weeks to maximum of 300mg daily (over 150mg in divided
doses); usual maintenance dose 100–300mg daily
SNRIs
Venlafaxine Efexor® XL Pfizer GAD
l 75mg once daily, increased if necessary at intervals of at least
2 weeks. Maximum dose of 225mg once daily
Social anxiety disorder
l 75mg once daily, increased if necessary at intervals of at least
2 weeks. Maximum dose of 225mg once daily
Duloxetine Cymbalta® Eli Lilly GAD
l 30mg daily, increased if necessary to 60mg once daily. Maximum
dose of 120mg daily
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Appendix 3 Literature search strategies
TABLE 8 OVID: MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to present
(initially searched 9 September 2013)
# Term
Number of
identified studies
1 exp Anxiety Disorders/ 67,490
2 ((anxi$ adj2 disorder) or (neuro$ adj2 worr$) or (neuro$ adj2 state$)).tw. 12,999
3 (obsess$ adj2 compuls$).tw. 11,554
4 ocd.ti,ab. 5785
5 (post adj2 trauma$).tw. 20,194
6 ptsd.ti,ab. 12,360
7 (social adj2 (phobi$ or anxi$)).tw. 6584
8 panic.ti,ab. 11,765
9 or/1-8 98,677
10 exp Treatment Failure/ 27,346
11 (refract$ or resistan$ or nonrespon$ or non-respons$ or unrespon$ or fail$ or
(incomplet$ adj respon$) or (no$ adj2 respon$)).tw.
1,672,308
12 (inadequat$ respon$ or (sub$ adj2 respon$) or (poor$ adj respon$)).tw. 44,440
13 or/10-12 1,713,541
14 (adult$ or mature or full-grown or full grown or old$ or senior or elder or aged or geriatr$
or middleage$ or middle-age or late$ life or pension$ or late$ onset$).ti,ab.
2,076,736
15 exp Adult/ 5,571,109
16 exp Aged/ or exp Middle Aged/ or exp Retirement/ 3,866,883
17 or/14-16 6,602,926
18 limit 17 to (“middle age (45 to 64 years)” or “middle aged (45 plus years)” or “all aged
(65 and over)” or “aged (80 and over)”)
3,863,723
19 9 and 13 and 18 2295
20 exp cohort studies/ 1,351,785
21 cohort$.tw. 276,045
22 controlled clinical trial.pt. 89,120
23 epidemiologic methods/ 30,831
24 limit 23 to yr=1966-1989 11,289
25 exp case-control studies/ 655,023
26 (case$ and control$).tw. 331,389
27 (case$ and series).tw. 120,725
28 or/20-22,24-27 1,960,600
29 19 and 28 821
30 Randomized Controlled Trials as Topic/ 101,374
31 randomized controlled trial/ 384,981
continued
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TABLE 8 OVID: MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to present
(initially searched 9 September 2013) (continued )
# Term
Number of
identified studies
32 Random Allocation/ 81,084
33 Double Blind Method/ 130,411
34 Single Blind Method/ 19,282
35 clinical trial/ 501,321
36 clinical trial, phase i.pt 15,983
37 clinical trial, phase ii.pt 26,581
38 clinical trial, phase iii.pt 9981
39 clinical trial, phase iv.pt 963
40 controlled clinical trial.pt 89,120
41 randomized controlled trial.pt 384,981
42 multicenter study.pt 179,583
43 clinical trial.pt 501,321
44 exp Clinical Trials as topic/ 293,751
45 (clinical adj trial$).tw 222,887
46 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw 133,162
47 PLACEBOS/ 33,587
48 placebo$.tw 166,857
49 randomly allocated.tw 16,984
50 (allocated adj2 random$).tw 19,557
51 or/30-50 1,209,986
52 case report.tw 200,646
53 letter/ 821,957
54 historical article/ 298,696
55 or/52-54 1,309,918
56 51 not 55 1,179,947
57 19 and 56 599
58 29 or 57 1209
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TABLE 9 OVID: EMBASE (searched from inception to 9 September 2013)
# Term
Number of
identified studies
1 exp Anxiety Disorders/ 140,768
2 ((anxi$ adj2 disorder) or (neuro$ adj2 worr$) or (neuro$ adj2 state$)).tw. 16,558
3 (obsess$ adj2 compuls$).tw. 15,206
4 ocd.ti,ab. 7611
5 (post adj2 trauma$).tw. 25,631
6 ptsd.ti,ab. 14,870
7 (social adj2 (phobi$ or anxi$)).tw. 8321
8 panic.ti,ab. 15,072
9 or/1-8 171,198
10 exp Treatment Failure/ 79,790
11 (refract$ or resistan$ or nonrespon$ or non-respons$ or unrespon$ or fail$ or
(incomplet$ adj respon$) or (no$ adj2 respon$)).tw.
1,980,617
12 (inadequat$ respon$ or (sub$ adj2 respon$) or (poor$ adj respon$)).tw. 53,340
13 or/10-12 2,047,630
14 (adult$ or mature or full-grown or full grown or old$ or senior or elder or aged or geriatr$
or middleage$ or middle-age or late$ life or pension$ or late$ onset$).ti,ab.
2,527,084
15 aged/ 2,201,410
16 exp middle aged/ 1,154,678
17 exp pensioner/ 868
18 exp retirement/ 10,352
19 or/14-18 4,748,715
20 limit 19 to (adult < 18 to 64 years> or aged <65+ years>) 3,181,884
21 9 and 13 and 20 2680
22 exp cohort analysis/ 157,783
23 exp longitudinal study/ 64,462
24 exp prospective study/ 249,085
25 exp follow up/ 743,046
26 cohort$.tw. 359,921
27 exp case control study/ 89,362
28 (case$ and control$).tw. 418,496
29 exp case study/ 21,169
30 (case$ and series).tw. 155,754
31 or/22-30 1,769,502
32 21 and 31 772
33 Clinical trial/ 892,685
34 Randomized controlled trial/ 358,000
35 Randomization/ 63,374
continued
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TABLE 9 OVID: EMBASE (searched from inception to 9 September 2013) (continued )
# Term
Number of
identified studies
36 Single blind procedure/ 18,220
37 Double blind procedure/ 119,966
38 Crossover procedure/ 38,383
39 Placebo/ 237,722
40 Randomi?ed controlled trial$.tw. 93,836
41 Rct.tw. 12,545
42 Random allocation.tw. 1335
43 Randomly allocated.tw. 19,845
44 Allocated randomly.tw. 1942
45 (allocated adj2 random).tw. 814
46 Single blind$.tw. 14,148
47 Double blind$.tw. 146,578
48 (treble or triple) adj (blind$).tw. 352
49 Placebo$.tw. 200,245
50 Prospective study/ 249,085
51 or/33-50 1,392,985
52 Case study/ 21,169
53 Case report.tw. 261,442
54 Abstract report/ or letter/ 903,642
55 or/52-54 1,180,920
56 51 not 55 1,355,531
57 21 and 56 576
58 32 or 57 1116
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TABLE 10 Cochrane Controlled Trials Register (searched from inception to 9 September 2013)
# Term
Number of
identified studies
1 MeSH descriptor: [Anxiety Disorders] explode all trees 4447
2 ((anxi* near/2 disorder) or (neuro* near/2 worr*) or (neuro* near/2 state*)):ti,ab,kw 3915
3 (obsess* near/2 compuls*):ti,ab,kw 1276
4 ocd:ti,ab,kw 594
5 (post near/2 trauma*):ti,ab,kw 1451
6 ptsd:ti,ab,kw 930
7 (social near/2 (phobi$ or anxi*)):ti,ab,kw 609
8 panic:ti,ab,kw 1885
9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 8882
10 MeSH descriptor: [Treatment Failure] explode all trees 2537
11 refract* or resistan* or nonrespon* or non-respons* or unrespon* or fail* or
(incomplet* adj respon*) or (no* near/2 respon*):ti,ab,kw
92,549
12 (inadequat* near/1 respon* or (sub* near/2 respon*) or (poor* near/1 respon*)):ti,ab,kw 4157
13 #10 or #11 or #12 95,403
14 MeSH descriptor: [Adult] explode all trees 1133
15 (adult* or mature or full-grown or full grown or old* or senior or elder or aged or geriatr*
or middleage* or middle-age or late* life or pension* or late* onset*):ti,ab,kw
432,233
16 #14 or #15 432,233
17 #9 and #13 and #16 931
DOI: 10.3310/hta18500 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 50
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Barton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
TABLE 11 PsycINFO (searched from inception to 9 September 2013)
# Term
Number of
identified studies
1 exp Anxiety Disorders/ 58,238
2 ((anxi$ adj2 disorder) or (neuro$ adj2 worr$) or (neuro$ adj2 state$)).tw. 12,854
3 (obsess$ adj2 compuls$).tw. 15,008
4 ocd.ti,ab. 6642
5 (post adj2 trauma$).tw. 8805
6 ptsd.ti,ab. 18,406
7 (social adj2 (phobi$ or anxi$)).tw. 10,397
8 panic.ti,ab. 13,143
9 or/1-8 81,499
10 (refract$ or resistan$ or nonrespon$ or non-respons$ or unrespon$ or fail$ or
(incomplet$ adj respon$) or (no$ adj2 respon$)).tw.
192,150
11 (inadequat$ respon$ or (sub$ adj2 respon$) or (poor$ adj respon$)).tw. 10,291
12 10 or 11 200,653
13 (adult$ or mature or full-grown or full grown or old$ or senior or elder or aged or geriatr$
or middleage$ or middle-age or late$ life or pension$ or late$ onset$).ti,ab.
678,919
14 9 and 12 and 13 1516
15 ((case* adj5 control*) or (case adj3 comparison*) or case-comparison or control group*).ti,
ab. not “Literature Review”.md.
62,969
16 (cohort or longitudinal or prospective or retrospective).ti,ab,id. or longitudinal study.md. or
prospective study.md. or retrospective study.md. not “Literature Review”.md.
169,825
17 15 or 16 226,508
18 14 and 17 145
19 clinical trials/ or “treatment outcome clinical trial”.md. or ((randomi?ed adj7 trial*) or
((single or doubl* or tripl* or treb*) and (blind* or mask*)) or (controlled adj3 trial*) or
(clinical adj2 trial*)).ti,ab,id.
68,682
20 14 and 19 179
21 18 or 20 299
TABLE 12 Web of Science (searched from 2000 to 9 September 2013)
# Term
Number of
identified studies
1 (anxiety disorder or neurotic or neurotic state or ocd or ptsd or post trauma or panic
or phobia)
73,338
2 ((inadequate response or poor response or refract* or resistan* or nonrespon* or
non-respon* or unrespon* or fail))
1,067,419
3 (adult or old or senior or elder or aged or geriatr* or middleage* or middle-age* or late*
life or pension* or late* onset)
2,053,501
4 #1 and #2 and #3 1422
5 Limit 4 to article, meeting abstract, proceeding paper or correction 1255
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Appendix 4 Table of excluded studies
with rationale
Excluded study Reason for exclusion
Abelson et al.101 Not population of interest (all people aged < 65 years)
Aboujaoude et al.102 Not study type of interest (single arm)
Allgulander103 Not study type of interest (review)
Altamura et al.104 No subgroup by age
Amiaz et al.105 Not population of interest (inclusion criterion of age of 18–65 years)
Anderson et al.106 Not study type of interest (letter)
Atmaca et al.107 Not population of interest (all people aged < 65 years)
Barr et al.108 No subgroup by age
Bartzokis et al.109 Not population of interest (all people aged < 65 years)
Blank et al.110 Not population of interest (not treatment resistant)
Blay et al.111 Not study type of interest (review)
Brawman-Mintzer et al.112 No subgroup by age
Bresolin et al.113 Not population of interest (not treatment resistant)
Bruno114 No subgroup by age
Buchsbaum et al.115 No subgroup by age
Campanini et al.116 No subgroup by age
Carey et al.117 Not population of interest (all people aged < 65 years)
Carr et al.118 Not population of interest (all people aged < 65 years)
Crocq et al.119 Not population of interest (all people aged < 65 years)
Csigo et al.120 No subgroup by age
Dannon et al.121 No subgroup by age
David et al.122 No subgroup by age
Denys et al.123 Not population of interest (inclusion criterion of age of 18–65 years)
Depping et al.124 Not study type of interest (review)
Di et al.125 Not population of interest (all people aged < 65 years; inclusion criterion of age of
18–45 years)
Dick et al.126 No subgroup by age
Diniz et al.127 Not population of interest (inclusion criterion of age of 18–65 years)
Diniz et al.128 Not population of interest (inclusion criterion of age of 18–65 years)
Erzegovesi et al.129 Not population of interest (inclusion criterion of age of 18–65 years)
Fallon et al.130 Not population of interest (all people aged < 65 years)
Fava et al.131 No subgroup by age
Fineberg et al.132 No subgroup by age
Fineberg et al.133 Not study type of interest (review)
Geus et al.134 Not population of interest (inclusion criterion of age of 18–65 years)
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Excluded study Reason for exclusion
Ginsberg95 Unable to obtain
Goodman et al.135 Not population of interest (all people aged < 65 years)
Haghighi et al.136 No subgroup by age
Hinton et al.137 Baseline characteristics not reported
Hinton et al.138 No subgroup by age
Hinton et al.139 No subgroup by age
Hinton et al.140 No subgroup by age
Hirschmann et al.141 No subgroup by age
Hoffart et al.142 No subgroup by age
Hofmann et al.143 Not study type of interest (review)
Hollander et al.144 No subgroup by age
Huff et al.145 Not population of interest (inclusion criterion of age of 21–65 years)
Ipser et al.63 Not study type of interest (review)
Kampman146 Not population of interest (all people aged < 65 years)
Kang et al.147 No subgroup by age
Katz148 Not study type of interest (review)
Khan et al.149 Abstract only; insufficient information to assess
Kolivakis et al.150 Not study type of interest (book chapter)
Koran et al.81 Not population of interest (all people aged < 65 years)
Koran et al.151 Not population of interest (all people aged < 65 years; inclusion criterion of age of
18–55 years)
Koran et al.152 Not population of interest (all people aged < 65 years)
Kordon et al.153 Not population of interest (all people aged < 65 years)
Krystal et al.82 No subgroup by age
Li et al.154 Not population of interest (all people aged < 65 years)
Lippitz et al.155 Not population of interest (not treatment resistant)
Lohoff et al.156 Baseline characteristics not reported
Macklin et al.157 No subgroup by age
Maina et al.158 No subgroup by age
Mallet et al.159 Not population of interest (all people aged < 65 years)
Mansur et al.160 Not population of interest (inclusion criterion of age of 18–65 years)
Mantovani et al.161 No subgroup by age
Marshall et al.162 Not population of interest (not treatment resistant)
Matsunaga et al.163 No subgroup by age
Mavissakalian164 Not population of interest (includes people who are not treatment resistant)
McDougle et al.165 Not population of interest (all people aged < 65 years)
McDougle et al.166 No subgroup by age
McDougle et al.167 Not population of interest (most people aged < 65 years; only 2 people were aged ≥ 65 years)
McDougle et al.168 Not population of interest (all people aged < 65 years)
Menza et al.169 Not population of interest (inclusion criterion of age of 18–65 years)
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Excluded study Reason for exclusion
Mithoefer et al.170 No subgroup by age
Muscatello et al.171 No subgroup by age
Nakatani et al.172 Not study type of interest (single arm study; no control group)
Ninan et al.173 No subgroup by age
Nuttin et al.174 Not population of interest (all people aged < 65 years)
Okun et al.175 Not question of interest
Osuch et al.176 Not population of interest (all people aged < 65 years)
Oude Voshaar et al.177 Not study type of interest (review protocol)
Peet et al.178 No subgroup by age
Pittenger179 Not study type of interest (single arm study; no control group)
Pollack180 Not study type of interest (single arm study; no control group)
Pollack et al.181 No subgroup by age
Prasko et al.182 Not population of interest (all people aged < 65 years; inclusion criterion of age of
18–45 years)
Prasko et al.183 Not population of interest (all people aged < 65 years)
Raskind et al.184 Not population of interest (not treatment resistant)
Ravizza et al.185 No subgroup by age
Rickels et al.186 No subgroup by age
Sachdev et al.187 No subgroup by age
Sachdev et al.83 No subgroup by age
Sayyah et al.188 Not population of interest (all people aged < 65 years)
Schutters et al.189 Not population of interest (includes people who are not treatment-resistant)
Selvi et al.190 Not population of interest (inclusion criterion of age of 18–65 years)
Shapira et al.191 No subgroup by age
Simon et al.192 No subgroup by age
Simon et al.193 No subgroup by age
Simon et al.194 Not population of interest (all people aged < 65 years)
Skapinakis et al.195 Not study type of interest (review)
Stanley et al.196 Not population of interest (not treatment resistant)
Stein et al.197 Baseline characteristics not provided
Stein et al.198 No subgroup by age
Storch84 No subgroup by age
Tarrier et al.199 Not population of interest (not treatment resistant)
Thorén et al.200 Not population of interest (all people aged < 65 years)
van Balkom et al.201 No subgroup by age
Wurthmann et al.202 Not population of interest (inclusion criterion of age of 18–65 years)
Zhang et al.85 Not population of interest (all people aged < 65 years)
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